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Cytochrome P450s are a large superfamily of enzymes in humans with little 
sequence homology, but a conserved fold. The flexibility of P450s, particularly of 
their substrate recognition site (SRS) is well-documented and enables them to bind 
a multitude of ligands with diverse physico-chemical properties, however the 
dynamic factors controlling the flexibility are not clearly understood. In order to gain 
better understanding of conformational flexibility inherent in P450s, NMR studies 
were performed on a model P450 system, CYP101A1, to characterize the dynamic 
differences exhibited by this P450 upon binding to a suite of 4 different ligands. 
Different ligand-bound forms of the protein were prepared, isotopically labeled and 
used to obtain sequence-specific resonance assignments throughout the protein 
using multidimensional NMR experiments. Molecular docking was carried out to 
elucidate a model structure of CYP101A1 in complex with one of the ligands, 
ketoconazole, as there is no crystal structure available for this complex. The new 
structural data and resonance assignments allowed interpretation of amide 
exchange rates encoding slow timescale motions for the various ligand-bound 
forms in comparison to the ligand-free form of CYP101A1, which showed 
significant differences in slow timescale dynamics for not just the SRS, but also 
regions outside of the SRS. The results from the amide exchange studies clearly 
show that CYP101A1 exhibits differential dynamics for binding various ligands 
even though they all have the same affinity to the enzyme. The dynamic 
measurements were complemented by thermodynamic data from ITC 
measurements which helped connect the dynamic differences in the various 
ligand-bound forms of the protein to the thermodynamic characteristics via a novel 
enthalpy-entropy transduction mechanism, which has not been experimentally 
demonstrated so far for a P450. Understanding of this mechanism will aid in 
gaining deeper insights into how P450s are able to modulate their dynamics for 
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CYTOCHROME P450 DYNAMICS IN LIGAND RECONGITION 
 
1.1 Protein Dynamics 
    
Proteins are not static but dynamic entities, where dynamics of the protein apart 
from structure often play a critical role in executing said functions [2]. While traditionally 
the study of enzymes has emphasized their structural elements in relation to their 
function, more evidence points towards the dynamics of the protein playing an integral 
role. Protein function often requires the proteins to maintain a certain level of flexibility 
and dynamic movement. Protein dynamics can be defined as a reversible time 
dependent movement from atom coordinates [3]. The dynamics are not limited to a 
single time scale, and can occur on several time scales depending on the structural 
level (Figure 1) [4]. Slow timescale movements (s-min) include movements such as the 
global collective motions of the protein. The intermediate timescale (μs-ms) 
encompasses movements like folding and domain movements. The intermediate time 
scale also includes motions associated with both ligand binding and catalysis. The fast 











1.2  Methods for characterizing protein dynamics 
 
Different techniques are specialized to examine the different time scales of 
motion. For example, stopped flow methods can study fast picosecond-nanosecond 
timescale motions, whereas Forster resonance energy transfer (FRET) is a technique 
that can be utilized to study the intermediate time scale motions in the nanosecond to 
microsecond range.  FRET is based on adding fluorophore tags that absorb different 
wavelengths of lights to the two areas or molecules that potentially interact. If the tags 
encounter one another, the florescent signal will change due to resonance energy 
transfer, which can be tracked and used to get both structural and dynamic information 
[6]. One large disadvantage of this technique is that the tag introduces an artificial 
element that can affect the protein’s structure and ability to fold. It also does not have 
resolution at the atomic level. Single-molecule FRET is also an increasingly popular 
technique that is being utilized increasingly to study conformational dynamics of a 
protein. This technique has the advantage that it is not an averaged ensemble of 
structures and thus can show details at a single-molecule level that are obscured by the 
ensemble, like kinetic information when a system is at equilibrium [7, 8]. However, such 
details cannot be obtained experimentally at atomic resolution and have to be combined 
with MD simulations to interpret results. 
X-ray crystallography is another alternative than can be used to look at fast time 
scale motions.  Interpretation of the electron density using time-resolved crystallography 
can show dynamics at the atomic level in the ps- μs range [9]. One group used 
picosecond time-resolved Laue diffraction methods to compare wild type and a mutant 
myoglobin’s motions in the time range of 100 ps to 3 μs [10]. However, there are some 
significant limitations to this technique. First, this method normally requires large 
quantities of protein, especially in the crystallization setup, crystal growth and screening 
process. Second, crystals will only form under certain conditions, which may not be 
representative of the conditions that the protein will face in actuality in solution. Thus, 
only a partial representation of conformations available to the protein can be obtained. 
Molecular dynamics is an in-silico method that is heavily utilized to look at fast 
time scale motions and is often used as a complement to experimental data.  Molecular 
dynamics is able to compute probable protein motions with great accuracy for motions 
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in the fs-ps time scale [11]. This technique can provide atomic resolution when paired 
with complementary experimental techniques such as neutron scattering or 
crystallography.  This can act as limitation on molecular dynamics, as it does require 
robust experimental validation. 
Spectroscopic techniques overcome some of the limitations in resolution, protein 
amounts, non-native conditions and modification to proteins, as dynamic motions can 
largely be studied experimentally using methods such as electron paramagnetic 
resonance (EPR) and nuclear magnetic resonance (NMR) spectroscopy under 
physiological conditions without any tagging or outside perturbations, giving a less 
biased picture of the protein motions [12]. EPR can be used to study motions in the ns-
μs time scale range and monitors changes in linewidths to interpret dynamic motions 
[13]. Solution NMR spectroscopy in particular provides information at the atomic level 
on all three timescales of motion and is one of the primary techniques used to study 
protein dynamics [14]. Solution NMR allows for multiple conformations of the protein to 
be represented at once which can be detected at high resolution and even time-
dependent transitions between the conformations can be characterized in great detail. 
Another advantage of NMR in study of dynamics is that it typically uses lower 
concentrations of protein compared to similar methods.   
A variety of solution NMR methods are available to characterize molecular 
motion in solution. The most prominent among them are hydrogen-deuterium exchange 
(HDX) experiments that monitor ms-min slow timescale motions on the protein 
backbone by NMR. HDX as a technique is not limited to NMR and can also be used 
alternatively in mass spectrometry or in conjunction with NMR, however NMR typically 
provides higher atomic resolution in a site-specific manner[15]. This method involves 
monitoring decreasing peak intensity in a two-dimensional 1H-15N correlation spectrum 
over time after exposure to D2O due to the so called overall “breathing” motions of the 
protein which opens up and closes water access channels to the interior of the protein 
resulting in exchange of hydrogens attached to nitrogen with deuterium as a function of 
this motion. 
The intermediate time scales of motion on the other hand can be captured using 
the transverse relaxation rates for protein backbone N-H and side-chain C-H bonds 
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utilizing the Carr–Purcell–Meiboom–Gill (CPMG) pulse sequence. This technique works 
by measuring T2 relaxation time modulation under chemical shift refocusing conditions 
or lineshape analysis to get rates for chemical exchange in the μs-ms time frame [16]. 
Such measurements are highly useful to characterize important functional motions of 
proteins involved in catalytic activity, recognition events such as protein-protein and 
protein-ligand interactions as well as folding-unfolding events.     
Finally, backbone amide relaxation experiments can be performed to monitor the 
fast ps-ns timescale of protein motion. These allow two relaxation time parameters to be 
measured which can be used indirectly to quantify protein motion: The T1 time, which is 
the spin-lattice relaxation time, and T2, which is the spin-spin transverse relaxation 
time[17]. These nuclear spin rates can be monitored in a residue-specific manner within 
the protein to get a sense of motions such as isotropic and anisotropic backbone 
movements by calculating order parameters along with any relevant chemical exchange 
rates for transitions between protein conformations as part of these movements.   
 
1.3 Cytochrome P450 Enzymes 
 
Enzymes are proteins that perform a specialized function, namely catalysis of a 
specific reaction, converting substrates into products. This function typically involves 
movement of structural elements, mainly in the catalytic site, as part of dynamic motions 
of the protein. Cytochrome P450s are a super family of enzymes that are found in every 
kingdom of life, with over a million estimated unique P450s in existence[18].  P450s are 
monooxygenases, which add an oxygen to a carbon hydrogen bond. While the 
substrates of P450s may vary, all P450s share a conserved reaction mechanism [19].  
The typical general reaction catalyzed by P450s is represented in equation (1) and is 
performed to make a more soluble product compared to the substrate. The solubility of 
the products helps with reducing the toxicity of the substrates by safely discarding them 
through aqueous means and can act as a defense mechanism in metabolism of 
xenobiotic compounds. 
 
RH + O2 + 2 e




The catalytic mechanism starts when a substrate binds to the enzyme (Figure 2) [1].  
Once the substrate is bound, the iron in the heme is reduced from its +3 oxidation state 
to +2 oxidation state by an electron donor, like NADPH or ferredoxin, to move forward in 
the catalytic cycle [20]. Oxygen binds in the next step in the mechanism and gets 
converted to radical form by accepting an electron from the iron in the heme. Only after 
the completion of this step will a second electron be accepted, making an iron-oxene. 
Two protons then enter the system and form one molecule of water with one of the 
oxygen atoms, leaving behind an oxygen-iron complex.  This causes rearrangement at 
the heme center, which allows for the hydroxylation of the substrate to product by using 











Figure 2: Conserved P450 reaction mechanism  [1] 
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While cytochrome P450s are present in most organisms, the primary use of them 
can vary greatly.  In plants, a typical function is to use P450s to generate secondary 
metabolites to defend against stressors, such as pesticides or bacterial infections [21]. 
Plant P450s have also been associated with the ability of microbes to colonize plant 
roots [22]. Bacteria utilize P450s as part of their metabolic processes or in sterol 
biosynthesis[23]. In humans, P450s are used primarily for xenobiotic processing, fatty 
acid metabolism, and hormone synthesis [24]. Another area where P450s have been 
utilized is biocatalysis, as the chemical reactions they help carry out is very costly 
without them and requires very high heat to facilitate when the enzymes are not used 
[25]. 
The ability to activate carbon-hydrogen bonds gives these enzymes an important 
role in the metabolism of xenobiotics as well as in endogenous synthesis of ligands. 
There are 57 human P450s that are primarily expressed in the liver and constitute 80% 
of drug metabolism activity in humans [26], [27]. CYP3A4 is the most abundant of 
human liver P450s and processes more than 50% of the oxidatively metabolized drugs 
[28]. However, the metabolic activity of CYP3A4 can vary greatly in individuals due to 
presence of genetic polymorphisms. There are more than 78 known single nucleotide 
polymorphisms (SNPs) for this protein, and certain isoforms have been associated with 
an increased cancer risk [29]. This SNP problem is not just restricted to CYP3A4. 
Another human P450 that exhibits a large number of SNPs is CYP2C9.  CYP2C9 
comprises approximately 20% of the total liver P450 content, making it one of the major 
human metabolic P450s [30]. There are 30 different SNPs currently identified for the 
CYP2C9 gene, but there are only 5 isoforms expressed in significant amounts [31]. 
These isoforms vary in their ability to process drugs, leading to differential drug efficacy 
and toxicity. Individuals can be categorized into three phenotypic categories; extensive 
drug metabolizers, intermediate drug metabolizers, and poor drug metabolizers, 
depending on which copies of CYP2C9 are present in their genome as well as which 
drug is being metabolized [32]. Notably, all of the mutations for the five major 
polymorphisms are outside of the active site or do not directly participate in the catalytic 
activity for CYP2C9.  This indicates an allosteric effect on either substrate binding or 
catalysis, via regions previously not associated with substrate binding and catalysis.  
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Because of their significant role in drug metabolism, P450s are a major drug target and 
are of much interest to the pharmaceutical industry [24]. However, the presence of 
SNPs complicates the drug development process due to individual metabolic variations. 
Between these various roles and research into effects of SNPs, P450s make up a 
multibillion-dollar industry. 
 Despite little sequence homology and only a few conserved catalytic 
residues, all P450s still share a common fold and heme prosthetic group.  For example, 
despite there only being approximately 15% sequence homology between CYP2C9 and 
the bacterial P450 CYP101A1, the fold is fairly similar and the same general structure is 
maintained (Figure 3).  This conserved fold can be seen in the major secondary 
structure elements in and around the active site, such as the helix that anchors the 
heme group or the number of key structural elements involved in substrate binding. The 
family loses it similarities however when looking at the type of interactions in the regions 
associated with substrate binding, or the specific substrate recognition site (SRS).  The 
secondary structure elements that make up this region can be variable between how 
they adapt structurally and dynamically to different substrates in different P450s, which 
lends to the ability of P450s to bind to a wide array of diverse substrates. For the P450s 
to be able to bind substrates with different physical and chemical properties, they must 
be able to readjust the secondary structures in the SRS to match the features of that 
particular substrate. These rearrangements must be dynamic to facilitate binding, 
making the dynamics and substrate binding inextricable.  The proteins must also 
maintain a certain level of flexibility not just in the SRS, but throughout the protein to 
make this possible.  Studies have shown that the loop that closes the substrate channel, 
known as the F-G loop, which is common to all P450s, is very flexible [33] and works in 
tandem with other flexible elements of the SRS to accomplish ligand binding. In this 
research project, we have examined this flexibility by studying differential substrate 





Figure 3: Comparison of bacterial (CYP101A1) and human P450 (CYP2C9) 
structures showing common fold and secondary structure elements. CYP101A1 
























CYP101A1 (P450cam or CYP101) isolated from the bacteria Pseudomonas putida 
was the first P450 in the entire cytochrome P450 superfamily to be purified, crystallized 
and have its structure solved [34]. CYP101 inserts an oxygen atom into a C-H bond of 
its natural substrate, camphor, to synthesize 5-exo-hydroxycamphor which can then be 
metabolized further by the bacteria to generate energy. CYP101 follows the same 
catalytic reaction scheme as other P450s shown in Figure 1.  CYP101 is reduced by its 
redox partner, the ferredoxin protein putidaredoxin (Pdx), in two separate steps to 
complete the reaction. Pdx is the only electron donor that CYP101 can use to complete 
the mechanism, and mechanistic studies have found that, besides the contribution of 
electrons, there is also a specific effector role for Pdx in the mechanism [35]. 
The active site of the P450 family is well conserved, and CYP101 is no exception 
(Figure 4). It has multiple conserved residues found on the I helix and β-3 loop of the 
protein, which is buried inside and away from the bulk solvent. These residues include a 
cystine (C357) coordinates with the heme through its sulfur atom, anchoring it to the L 
helix, and a threonine-asparagine pair (D251-T252) that act as part of the 
proton/electron transfer pathway for protonation of oxygen to water. Mutations of T252 
results in the uncoupling of proton transfer and the production of peroxide instead, and 
mutations to D251 result in reduced electron transfer. D251 has also been implicated in 
substrate access to the active site [36]. Tyrosine 96 on the B’ helix plays a role in 
camphor’s orientation in the active site by hydrogen bonding to the oxygen atom to keep 
it in place. All substrates, not just camphor, upon binding displace a water molecule that 
coordinates with the 6th coordination site on the heme, which frees that site up for 
oxygen binding.  In the case of inhibitors, the inhibitor will bind directly to the heme and 
occupy the same 6th coordination site, preventing oxygen’s attachment. Once the 
reaction has been completed, the product then exits the active site by a hydrophilic 





Figure 4: Active site of CYP101 bound to substrate camphor (top) and inhibitor 




The substrate binding and the catalytic conversion of substrate to product are 
two energetically independent events for P450s, with the substrate entering the enzyme 
through a channel that is distinct from the active site [37].  This channel whose opening 
is formed by the SRS for CYP101, consists of the F and G helices, connected by the FG 
loop, the β-5 sheet, a portion of the N terminal region and the B’ helix (Figure 5). These 
regions are very flexible and show the least conservation among all P450s [38].  
Important residues for these regions include Y29, F87, Y96 and F193, which show 
displaced side chains when bound to small or large ligands [39].  The channel can exist 
in an open state when no ligand is present and will convert to a closed state by moving 
the F and G helixes towards the heme via the FG loop after binding most ligands [37], 
making the distance the FG loop travels approximately 10 Angstroms between states 
(Figure 6). 
While the flexibility of the SRS is well-known, the dynamic motions that allow this 
flexibility is still not completely understood. Ligand-free CYP101 is believed to sample 
dynamically between open, partially open and closed states [40].There have only been 
a few experimental studies where the dynamics of P450s have been investigated in 
atomic detail. Most of these experimental studies have focused on CYP101 and other 
bacterial P450s. One study used 2D infrared vibrational echo spectroscopy to examine 
the dynamics of ligand-free, camphor-, and norcamphor-bound CYP101.  It was 
observed that the dynamics of residues in CYP101 active site was correlated with the 
affinity and hydroxylation of the substrates on the ps timescale. Camphor-bound 
CYP101 was found to be less dynamic than the norcamphor-bound form, which is in 
turn less dynamic than the ligand-free protein.[41] Dynamic studies on human P450s 
have been carried out mostly by MD simulations on short to long timescales [42, 43]. 
Focusing specifically at the SRS of CYP101, MD simulations verified with NMR data 
have also been utilized to understand the cis-trans isomerization of the ILE88-PRO89 at 
the start of the B’ Helix.  This study surmised that the switch between isomers happens 
on the fast timescale and is induced by the binding of Pdx, and leads to reorientation of 




Figure 5: CYP101 structure with regions corresponding to the substrate 





Figure 6: Superimposed structures of camphor-bound (blue) and the ligand-free 
(red) CYP101, showing the displacement (yellow double-headed arrow) of the FG 
Loop upon binding of camphor. CYP101 camphor-bound PDB id: 2CPP; ligand-
free PDB id: 3L62 
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CYP101 was carried out using NMR and mass spectrometry which found that the B’ 
helix exchanged out much quicker in the oxidized form of the protein compared to the 
reduced form [45]. A prior study utilizing NMR spectroscopy, neutron scattering and MD 
simulations compared the ligand-free form with the camphor-bound form in terms of 
backbone relaxation dynamics and found that the flexibility between the SRS and 
regions outside of the SRS in the protein is coupled via a network of interactions which 
helps modulate ligand binding [46]. The solution NMR 15N relaxation measurements on 
CYP101 in this study characterized fast backbone N-H motions with concomitant 
calculation of order parameters for camphor-bound and ligand-free CYP101, both 
experimentally and from hydrated powder MD simulations, which concluded that the 
SRS exhibited the largest dynamic changes in the ps-ns time range [46].  Regions 
outside of the SRS, specifically in the corner regions of the triangular structure of 
CYP101, also had small but significant changes in dynamics between the two forms. 
A more recent study employing inelastic neutron scattering of hydrated powders 
showed presence of fast motions on the ns timescales that are collective in nature. 
Normal mode analysis of the network of these motions shows that the protein uses 
these collective motions to move along a perpendicular axis from the ligand binding 
channel to open and close the channel [47].  Both the NMR and neutron scattering 
studies were only conducted with the ligand free or camphor-bound protein, and do not 
necessarily represent the whole range of dynamics and motions that CYP101 can 
undergo with ligands with differing physico-chemical properties. Such a dynamic 
characterization with multiple ligands is important to explain the wide range of ligand 
specificity observed for P450s in various species and organisms. This dynamic 
understanding can also be exploited in design of new drugs that are readily recognized 
by the flexible SRS and appropriately metabolized by human P450s in the active site 
alleviating some of the clinical issues apparent in case of hyper or poor drug-






1.5  Project goals 
 
The overall goal of this project is detailed characterization of P450 protein 
dynamics in context of multiple ligand recognition in a model P450 system providing 
valuable information that can be applied to other members of the P450 family to 
understand their diversity in ligand binding. CYP101 is a good prototypical system for 
such characterization for multiple reasons. For one, CYP101 can be expressed and 
purified as a soluble protein with soluble cofactors in large quantities. This makes it 
advantageous to use CYP101 rather than membrane-bound mammalian P450s which 
are notoriously difficult to express and purify in both soluble and membrane-bound 
forms at high concentrations. Second, the soluble form of CYP101 shows structural, 
dynamic and mechanistic aspects that are comparable to a large extent to soluble 
mammalian P450s with a tendency to bind similar ligands and exhibit large 
conformational changes similar to those observed in mammalian P450s [48]. Finally, 
native CYP101 was the first P450 crystallized in the late 1970s and hence is one of the 
most studied P450s, meaning there is a large foundation of biochemical and biophysical 
information available on it [34]. Since then, over 70 different structures have been 
solved for CYP101, in various mutant forms and bound to several ligands. Despite 
camphor being the natural substrate, CYP101 shows a high affinity for many other 
ligands, both substrates and inhibitors similar to mammalian P450s. This allows for the 
structural and dynamic examination of binding of the same or similar ligands that bind to 
human P450s, with the assumption that the dynamic mechanisms to effect binding of 
these ligands across multiple P450s are generally similar given the conservation of the 
SRS and the specific elements in these regions, although the catalytic specificity may 
vary. This has given impetus to use of CYP101 as a model system to understand the 
dynamic mechanisms that might operate in other P450s, especially human P450s. 
While X-ray crystallography can yield great structural insights on how a P450 may 
interact with a ligand in terms of static snapshots of ligand-bound and ligand-free 
structures with the accompanying structural changes, it does not provide a time-
dependent dynamic picture in context of ligand binding. For example, the crystal 
structures of CYP101 bound to most ligands are superimposable with minor changes 
due to freezing of protein conformations in forms that are easily crystallizable but may 
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not represent the most likely or diverse conformations observed in solution. This 
therefore does not reflect the entire range of ligand-dependent dynamic motion 
available to the protein that is observed for these same complexes in solution as 
observed in solution NMR measurements (Figure 7/8).  Looking at the spectra with 
different ligands, clear differences can been in the differential linewidths and peak 
splittings when CYP101 is bound to different ligands. NMR data clearly indicates that 
CYP101 is sampling multiple conformations in solution in a time-dependent manner that 
is not reflected in crystal structures. It is likely that these dynamic motions can be used 
to effect ligand binding by the SRS in a specific manner as has been suggested by 
preliminary evidence from previous NMR and neutron scattering studies, however what 
is not clear from these studies is whether the protein dynamics change upon binding of 
a different ligand and if so, how and to what extent?  
We aim to answer these questions in the current study by investigating the 
dynamic changes in CYP101 bound to various ligands using solution NMR 
spectroscopy. Previous dynamic work on CYP101 has been primarily carried out by 
comparing the dynamics of ligand-free oxidized CYP101 to only a single ligand-bound 
form i.e. camphor-bound CYP101. The current study aims to extend the dynamic 
investigation to a multitude of ligands and that too with differing physico-chemical 
properties in order to get an elaborate sense of the range of dynamics exhibited by the 
protein. This is the first such dynamic characterization for CYP101 and for that matter 
for any P450 in the superfamily and has potential to offer detailed insight into ligand 
binding dynamics at a level that goes beyond the current structural knowledge for this 
important family of enzymes. Since P450s are such an important drug target, this 
information is relevant to rational drug design, particularly in guiding flexible docking and 
screening of drugs using dynamic structural ensembles. NMR spectroscopy is a great 
technique for such dynamic characterization due to its ability to study these dynamic 
changes in solution on different timescales under physiological conditions. The main 
goal of the current study is therefore to look specifically at oxidized CYP101 dynamics 
on the slow timescales using NMR spectroscopy to try and get a comprehensive picture 
of the dynamic changes occurring upon binding of 4 different ligands that differ in their 




Figure 7: Solution NMR 1H-15N 2D HSQC-TROSY correlation spectra for oxidized 





Figure 8: Zoomed in Portions of 2D HSQC-TROSY spectra for oxidized CYP101 in 
ligand-free and various ligand-bound forms showing differences in linewidth 













PREPARATION OF CYP101 FOR EXPERIMENTS  
2.1 Cell growth and CYP101 protein expression  
 
A pET24 vector-based plasmid (Novagen) that encodes for CYP101 with a C-
terminal His6 tag and Kanamycin antibiotic resistance was used to transform calcium 
competent BL-21 E. coli cells (Stratagene Inc).  Transformed cells were plated on a LB 
medium plate containing 50 g/mL of the antibiotic Kanamycin and incubated overnight 
at 370C.  Colonies resistant to Kanamycin appeared on the plate in the morning, at 
which point a single colony of these cells was used to inoculate 50 mL of sterile LB 
broth containing 50 L of 50 mg/mL stock of Kanamycin.  Cells were incubated with 
shaking at 250 RPM and a temperature of 37 0C until cells reached an optical density of 
OD600=0.6. Cells were then transferred to sterile centrifuge tubes and centrifuged for 10 
minutes at 4OC and 6000 RPM.  The supernatant solution was decanted off and the 
remaining pellet was then suspended in 1L of enriched M9 media.  The enriched M9 
medium consisted of the following ingredients:  7.0g sodium phosphate dibasic 
anhydrous, 3.5g of potassium phosphate monobasic and 0.5g of sodium chloride/L, 
1mL of 50 mg/mL kanamycin, 1mL of 1M magnesium sulfate, 1g of ammonium chloride, 
4g of glucose, 75µL of 0.5 M iron(III) chloride, 100 µL of 1M calcium chloride, 1mL of 
trace metals (contents in g/L: 5 Na2EDTA; 0.05 FeCl3; 0.05 ZnCL2; 0.01 CuCl2; 0.01 
CoCl2.6H2O; 0.01 H3BO3; 1.6 MnCl2.6H2O), and 25 µL of 2% thiamine. The ammonium 
chloride was replaced with 15N labeled ammonium chloride and glucose replaced with 
13C6-Glucose to achieve 15N and 13C uniform labeling respectively of the protein. 
Cells were incubated with shaking at 250 RPM and 37oC in the enriched M9 
medium until they reached OD600=1, at which point the cells were induced to start 
protein expression with 1 mL of 1M isopropyl β-D-thiogalactopyranoside (IPTG).  35 
mg/L of delta-amino levulinic acid hydrochloride was also added at time of induction to 
serve as a heme precursor.  Cells were continued to shake for 12 hours at 37oC after 
induction, at which point they were harvested by centrifugation at 6000 RPM and the 
cell pellet stored at -80oC until use. 
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2.2 Protein Purification  
Frozen cells were resuspended in 60 mL of phosphate buffer A (50 mM KPO4, 
50mM KCl, pH=7.4) for every 15 g of cells. Once fully suspended, the cell mixture was 
then put on ice and sonicated in a pattern of 20 seconds on and 1 minute off for a total 
of 4 times with a Branson Sonifier 250. The lysate was centrifuged for 15 minutes at 
11000 RPM at 40C. The supernatant solution was then run through a second 
centrifugation cycle for 10 minutes at 11000 RPM at 40C to remove any remaining cell 
debris.  The resulting supernatant solution was passed through a Ni2+ metal affinity 
(Talon Metal Affinity Resin, Clontech Laboratories) column, which captures CYP101 via 
the C-terminal His6 tag.  The captured protein on the column was washed with 20x the 
column volume with buffer A and eluted with 125 mM imidazole in buffer A.  The eluate 
from Nickel column was then passed through a second column containing anion 
exchange resin Q Sepharose fast flow (GE Healthcare Life Sciences), washed with 20x 
the column volume witj buffer A and eluted with 250 mM KCl dissolved in buffer A. The 
eluted protein was then concentrated with a Millipore 30,000 MWCO centrifuge filter. 
The concentrated protein went through a final purification stage with a S100 size 
exclusion chromatography column (GE Life Sciences) running on an Amersham FPLC 
system.  1 mL fractions of CYP101 eluting from this column were collected and protein 
purity measured for them. Protein samples of oxidized CYP101 with a UV-Vis 
absorbance ratio of A391nm/A280nm greater than 1.4 were deemed to be at least 95% pure 
and were taken for further experiments. The concentration of the pure protein was 
determined via equation (2) 
  A418= εbc        Eqn. 2 
Where A418 is the absorbance value at 418nm, which is where the heme absorbs in the 
absence of ligand, ε is the extinction coefficient, which is 100 M−1 cm−1 for CYP101, b is 
the path length of 1cm of the UV vis cuvette and c is the molar concentration of the 
protein. The 418 nM peak is sensitive to ligand binding and undergoes a blue shift upon 
substrate binding near the heme and a red shift upon inhibitor binding to the heme and 
can be used as a measure to indicate binding of a ligand (Figure 9). Interestingly, the 
blue shift can also be seen with the naked eye by observing a color change of the 
protein from red (ligand-free) to brown (substrate bound). 
 
23 
2.3 Selection of ligands to probe CYP101 dynamics  
 
In order to comprehensively probe dynamic changes in CYP101 as a function of 
diverse ligand binding, a suite of 4 ligands was selected that differed in shape, size, 
chemical composition, binding affinities and binding site on the protein. The ligands 
used are shown in Table 1. Two substrates and two inhibitors were chosen, with varying 
affinities for CYP101. Camphor was the first substrate selected and is the natural 
substrate of CYP101, providing a base reference for the study as most previous 
structural and dynamic work on the CYP101 system has been on the camphor-bound 
form. Norcamphor was the other substrate chosen to be examined.  Norcamphor is 
structurally very similar to camphor, keeping the same overall structure. However, there 
are two main differences between norcamphor and camphor: 1) lack of 3 methyl groups 
on norcamphor relative to camphor and 2) different positioning of oxygen on the ring 
structure [Table 1].  This structural difference is enough to reduce the binding affinity 
(Kd) of CYP101 for norcamphor by 2 orders of magnitude compared to that for camphor, 
as norcamphor is unable to make certain noncovalent interactions with residues in 
CYP101 as camphor does.  Thus, use of these two different substrates allows us to 
probe the dynamics as a function of different substrate binding affinities. In the absence 
of Pdx, CYP101’s reaction cycle does not proceed beyond the protein-substrate resting 
state [35]. This allows us to look at substrate binding without the risk of conversion to 
product and without the addition of another inhibitor that could affect the dynamics.  
The two other ligands selected for this study are nicotine and ketoconazole, 
which differ greatly in size and chemical properties. Nicotine is a small ligand that binds 
directly to the iron in the heme with high affinity. Nicotine can act as either a substrate or 
inhibitor, depending on which P450 it is interacting with. In humans, P450s like CYP2A6 
and 2B6 use nicotine as a substrate for C-oxidation, whereas other P450s such as CYP 
2E1 see an inhibition by nicotine [49, 50]. While nicotine is hydroxylated by CYP101, it 
binds in a manner that is consistent with other CYP101 inhibitors.   Ketoconazole is an 
synthetic drug that is a derivative of phenylpiperazine, and is used as an antifungal drug 
due to its ability to inhibit microsomal P450s. Ketoconazole also inhibits CYP101, likely 
by binding directly to the iron, based on analysis of other P450 crystal structures bound 
to ketoconazole [51-53].  Ketoconazole is a bulky, hydrophobic ligand, but binds with a 
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surprisingly similar affinity as nicotine. Ketoconazole also binds to and inhibits human 
P450s in similar ways as they do to CYP101, implying medical relevance of 
understanding of their effects on P450 dynamics [54]. Overall, the range of ligands 
selected should give a comprehensive picture of CYP101’s dynamics with different 
types of ligands. The structure of CYP101 bound to 3 of the 4 ligands as well as the 
ligand-free structure has already been elucidated, providing a structural basis for the 























Table 1: List of ligands used to study dynamics of CYP101 
Ligand  Kd Classification  Structure  
Camphor  1 μM [55] Substrate, 
natural  
  































2.4 Preparation of NMR samples 
 
 The final sample preparation for the NMR experiments was similar for both 
resonance assignments and amide exchange experiments. The buffer solution 
consisted of 50 mM potassium phosphate (pH=7.4), 50 mM KCl, and trace amounts of 
β-mercaptoethanol.  Higher KCl concentration of 150 mM was used to ensure ligand 
solubility for ketoconazole and prevent aggregation effects. Spectra collected with 150 
mM KCl concentrations as well in the absence of β-mercaptoethanol did not show any 
detectable changes relative to the spectra in buffer containing 50 mM KCl and/or β-
mercaptoethanol indicating that the change in conditions do not affect the spectral 
patterns seen once ligands are added. Protein concentration between 0.15 mM and 0.4 
mM were used for various experiments in order to maximize signal intensity and 
resolution without protein aggregation. The hydrophobic ligand ketoconazole was 
dissolved in methanol before being added to the protein solution, while the other 3 
ligands were dissolved in the same buffer as the protein and used directly at the 
appropriate concentration. Each ligand was added into the ligand-free protein until 
saturation was reached, based on achievement of maximum shift in the protein heme 
resonance in UV-Vis spectra upon ligand binding. 
 
2.5 Preparation of Selective Isotope labeled samples of CYP101 
 
 CYP101 samples for ligand-free and all 4 ligand-bound forms were prepared 
with selective 15N labeling of different amino acid types and used for 2D 1H-15N HSQC-
TROSY spectral data collection. The protein samples were prepared and purified as 
described above, but with one major difference in that a single 15N isotopically labeled 
amino acid was added into the enriched M9 media along with 19 unlabeled amino acids 
and other ingredients. The amino acids were added as an amino acid mix in the 
followings amounts (g/L): 0.5 A, 0.3 R, 0.8 D, 0.4 N, 0.25 C, 0.5 G, 2.0 S, 0.3 H, 0.0 P, 
0.5 M, 1.0 E, 0.5 Q, 0.3 K, 0.3 F, 0.3 Y, 0.2 W, 0.5 L, 0.4 I, 0.5 T, and 0.5 V. The 
unlabeled amino acid was replaced with the appropriate 15N labeled amino acid 
depending on the amino acid type labeling desired. For example, for preparing a sample 
labeled selectively with 15N glycine, the unlabeled glycine in the amino acid mix was 
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replaced with the same amount of 15N labeled glycine, while the rest of the amino acids 
were added in unlabeled form. Selective labeling in this fashion allowed the collection of 
a 2D NMR 1H-15N HSQC-TROSY spectrum that will only contain the resonances for the 
labeled amino acid type.  The following amino acid types were labeled in this fashion: 
alanine, glycine, isoleucine, leucine, lysine, phenylalanine, and valine. These amino 
acid types were selected since they form the bulk of the amino acids found in CYP101 
and have little to no scrambling tendency of their labels to other amino acids during 
protein expression, thus allowing unambiguous selective identification of their peaks in 
NMR spectra. NMR spectra were collected and processed for each of these samples in 
ligand-free and all 4 ligand-bound forms in a similar manner to the uniformly labeled 
samples.   
 
2.6 Two- and Three-dimensional NMR experiments for resonance assignments  
  
All NMR experiments were run on a Varian 600 MHz spectrometer equipped with 
a cold probe. 1H-15N 2D correlation spectra with a HSQC-TROSY pulse sequence were 
collected on 15N uniformly labeled CYP101 samples to detect 2D amide resonances for 
ligand-free and all ligand-bound forms of the protein. A typical 1H-15N 2D experiment 
consisted of 16 scans acquired with 1024 complex points in the direct dimension and 
128 increments in the indirect dimension. Depending on the protein concentration, the 
number of scans were varied form sample to sample to acquire spectra with similar 
sensitivity. 
1H-15N-13C 3D correlation NMR experiments to assign backbone resonances 
were carried out for ligand-free protein and the 4 ligand-bound forms.  Standard 3D 1H-
detected TROSY versions of HNCA, HN(CO)CA and HNCO pulse sequences available 
on the Varian spectrometer were used to collect data sets for ligand-free and ligand-
bound forms (camphor, nicotine, and ketoconazole) of CYP101.  3D 1H-detected 
TROSY version of HNCACB pulse sequence was also used to collect data for camphor-
bound and ligand-free forms. Only the HNCO and HN(CO)CA data sets were collected 
for the norcamphor-bound form of CYP101 as the HNCA peak correlations are likely 
similar enough to the camphor-bound form that it would be possible to assign 
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resonances in norcamphor-bound form by comparison. A typical 3D experiment 
consisted of 16 scans acquired with 1024 complex points in the direct proton dimension, 
48 increments in the indirect carbon dimension and 32 increments in the indirect 
nitrogen dimension. The number of scans for each experiment was varied depending on 
sample concentration of a particular CYP101 form and to obtain sufficient sensitivity in 
peak correlations for data analysis.  
 The spectral data from all NMR 2D and 3D experiments described above was 
processed using NMRPipe software and analyzed using NMRViewJ software [57, 58]. 
The experiments were processed using sinusoidal and exponential window functions 
with a mild baseline correction. Linear prediction was applied in indirect dimensions with 
zero filling to double the number of points in the indirect dimensions and final spectra 
phase corrected before using for data analysis and resonance assignments. 
 
2.7 Collection of Amide exchange data  
 
H2O/D2O amide exchange (HDX) experiments were performed for ligand-free 
and all 4 ligand-bound forms of the CYP101 to monitor slow motions on the s-min 
timescale.  Ligand-bound samples were prepared with saturating concentrations of 
ligand present. In order to measure exchange of protonated amides with deuterium, a 
fully protonated 15N uniformly labeled sample was prepared and a 2D reference 
spectrum acquired initially. After the spectrum was collected, the protein was taken out 
of the NMR tube and lyophilized for a minimum of 12 hours to remove the hydrogenated 
solvent and taken to the NMR room. Just before the start of the HDX experiment, the 
lyophilized sample was quickly rehydrated with D2O and brought up to a similar volume 
as the sample used to collect the reference spectrum.  The lyophilized protein was 
checked for aggregation and stability by comparing the first collected spectra after 
exchange process was started to the reference spectrum collected before lyophilization 
and seeing similar peak characteristics for the peaks that were not exchanged out. 
Reference and all of the amide-exchanged 2D NMR 1H-15N HSQC-TROSY spectra 
were collected in a similar fashion to that described for resonance assignments with the 
number of scans reduced to 8 to obtain optimal spectra with sufficient signal intensity 
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but with frequent enough sampling of the amide exchange landscape to map out the 
exchange rates. After the exchange process was started, amide-exchanged spectra 
were collected every 28 minutes for approximately 40 hours to categorize both the fast 
and slow exchange rates. The first time point was collected within 5 minutes of the 
protein’s exposure to D2O to allow for detection of the fast exchange resonances. 
Samples were checked for stability by UV-Vis spectroscopy to ensure that the samples 
were stable through the length of the HDX experiments. All spectra were processed 
using NMRPipe and NMRViewJ in a similar manner to the ones used for resonance 
































SEQUENCE-SPECIFIC NMR RESONACE ASSIGNMENTS FROM 
MULITDIMENSIONAL HETERONUCLEAR EXPERIMENTS  
One of the most critical steps in NMR data analysis is to assign peaks in a 
sequence-specific manner for the protein.  For small proteins (<10 kDa), this process 
traditionally entails collection of multidimensional NMR spectra using 1H detected pulse 
sequences such as 2D COSY and 2D NOESY due to the high sensitivity of protons 
relative to other nuclei. This approach however fails for larger proteins that contain 
thousands of protons causing resonance overlap among the multitude of proton signals 
observed for such proteins. Efforts to resolve this resonance overlap are critical in 
resonance assignment of larger proteins such as CYP101. In our case, sequence-
specific backbone N-H resonance assignments are needed for the oxidized ligand-free 
and the 4 ligand-bound forms of CYP101 to characterize the dynamic differences 
between the forms, which required a strategy described below. 
3.1 Three-dimensional Heteronuclear NMR experiments for resonance 
assignments in CYP101 
 
Over the last three decades, 1H-detected pulse sequences have evolved to 
include heteronuclei such as 13C and 15N which makes it easier to employ pulse 
sequences for resonance assignment of large proteins that rely on building sequential 
connections among adjacent residues via heteronuclear signal editing, allowing 
backbone and side-chain assignments to be made with more ease. These sequences 
correspond to a suite of multidimensional (2D, 3D and 4D) heteronuclear experiments 
which allow correlations to be made between 1H from backbone and side-chains of 
amino acids in 13C,15N uniformly labeled proteins through heteronuclear scalar 
couplings to the specific heteronuclei that they are directly attached to (e.g. N, Cα, Cβ 
etc.). Several 3D heteronuclear experiments such as HNCA, HN(CO)CA, HNCO and 
HNCACB are available to build such correlations, originating from 1H magnetization 
which is then transferred to other nuclei via spin manipulation allowing correlation of 
multiple nuclei within an amino acid and also with nuclei in adjacent amino acids.  For 
example, in the HNCA experiment, the pulse sequence starts with the 1H magnetization 
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of the backbone amide of an amino acid, then transfers to the attached 15N via 
heteronuclear scalar coupling and then to the 13Cα of its own amino acid as well as the 
13Cα of the previous amino acid in the uniformly labeled 13C, 15N protein. Thus, this 
experiment will show the N, H and Cα chemical shift correlations for a residue(i) as well 
as the 13Cα chemical shift of the residue(i-1) previous to it in the sequence. This can be 
used to trace assignments along the protein sequence in a sequential manner. The 
HN(CO)CA experiment, on the other hand, manipulates spins in such a way that only 
correlations from the N-H chemical shifts of a certain amino acid to the previous 
residue’s Cα shift (i-1) via the intervening carbonyl group (CO), but not the self-residue’s 
Cα shift (i), are shown. This helps in resolving ambiguities about which resonances 
belong to self-amino acid and which belong to previous amino acids in the sequence.  
Similarly, the HNCO experiment will correlate the N-H chemical shifts of an amino acid 
to the carbonyl carbon chemical shift of the previous amino acid with which it forms a 
peptide bond with, again connecting one amino acid with the previous amino acid. 
HNCACB experiments correlate similar H, N and C chemical shifts as the HNCA, 
however offer even more refinement in determination of the self and previous amino 
acid’s identity by extending it to the Cβ shift for the self and previous amino acids along 
with the Cα shifts. The Cβ shifts are quite different for different amino acids and also 
differ in sign of peak intensity, which allows better discrimination of the identity of amino 
acids by amino acid type. The combination of HNCA, HNCO, HNCOCA and HNCACB 
experiments not only helps determine the identity of specific amino acids but allows 
building of connectivities for self and previous residues in a sequence-specific manner 
that can be walked backwards on to determine assignments for backbone N-H amide 

















Figure 10: 3D NMR heteronuclear resonance assignment experimental 
scheme.  Red circles indicate the chemical shifts of nuclei that will be 
visible in a certain experiment. Note that the N and H chemical shift in the 
HN(CO)CA experiment is correlating to the self. 
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3.2 Sequence-specific Assignments of various forms of CYP101 
 
In the case of CYP101, multidimensional heteronuclear NMR experiments such 
as those described above have been performed previously to obtain sequence-specific 
resonance assignments in various redox forms of CYP101. Two published data sets are 
available for the reduced form of CYP101 from Pochapsky’s group, which includes N, H 
and Cα chemical shifts (BMRB 19740 and 17415) [59, 60]. The reduced CYP101 data 
set makes available approximately 300 assignments for CYP101.  Additionally, two 
published data sets of NMR assignments (BMRB 5759 and 19038) are also available 
for the oxidized camphor-bound form of CYP101 from two different research groups [60, 
61]. These data sets obtained independently have approximately one hundred 
backbone N-H assignments, with significant overlap between the two sets. The large 
difference in number of assignments between oxidized and reduced CYP101 can be 
attributed to the presence of redox state of the heme group.  In the oxidized Fe3+ form at 
physiological temperature, the heme is paramagnetic and broadens out resonances 
within an 8-12 Angstrom distance, depending on the orientation of the heme group’s 
side prosthetic group and the fold of the protein polypeptide around the heme group. 
This causes the resonances to vanish from the multidimensional spectra in a random 
manner and breaks up the sequential connectivity in 3D NMR assignment experiments. 
This is not an issue in the reduced form of CYP101, as the iron gets converted to the 
Fe2+ state and switches from paramagnetic to diamagnetic, which does not have the 
same resonance broadening effect. Comparing the reduced and oxidized assignments 
of the protein will typically show large differences in the N and H chemical shifts but 
somewhat similar values for the Cα chemical shifts. This can be exploited to transfer 
some of the resonance assignments from the oxidized to the reduced CYP101 data 
sets, which is what was done by the two research groups in obtaining assignments for 
oxidized CYP101. 
In order to characterize protein dynamics throughout the protein for oxidized 
ligand-free and the 4 ligand-bound forms of CYP101, resonance assignments are 
needed for all 5 forms of the protein. However, the published data sets only provide  
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assignments for the camphor-bound form, hence the assignment process had to be 
carried out for the other forms. The chemical shifts in the spectra for each of the forms 
are distinct enough that transfer of backbone N-H assignments from one form to 
another was possible only for a few outlying peaks in spectra, however could not be 
accomplished with confidence for the regions in the middle of the spectra where there is 
significant overlap. Another compounding problem is that the number of available 
assignments in the camphor-bound form are not sufficient to provide adequate 
coverage for the dynamic regions of the protein, especially the SRS regions. This 
requires use of traditional sequential assignment strategy involving acquisition of 3D 
heteronuclear NMR spectra and analyzing the data from them independently for each of 
the CYP101 forms, which was not performed in the previously published work. 3D NMR 
data sets were therefore collected for each CYP101 form as described in the 
experimental section in Chapter 2 and the assignment process undertaken from the 
resulting data (Figure 11). The assignments obtained with this strategy were further 
confirmed and/or augmented with peak inferences made from selectively labeled 
spectra. 
There are several challenges in establishing NMR assignments for a protein such 
as CYP101. First, CYP101 has a large number of prolines (35) in its structure and 
because of proline’s unique amino acid structure lacking hydrogen in its backbone 
amide group, the N-H resonances for proline do not show up in 1H-detected 2D and 3D 
spectra. This can break up sequential connectivity when trying to work backwards in the 
3D datasets. Second, the paramagnetism of the heme group hampers establishing 
sequential connections, especially in regions close to the heme group such as the SRS 
and I helix. As discussed previously, the residues in the SRS are the most flexible of all 
regions in the protein and therefore it is crucial that maximum number of assignments 
are available in order to characterize the dynamic changes in these regions in a 
comprehensive manner. While certain residues are not visible for the SRS, the majority 
of the region is remote enough from the heme that approximately 41-48 of the 55 




Figure 11: Example of sequential assignment of a stretch of residues 387-390 




current project was primarily directed towards assigning the resonances for SRS in the 
protein, however additional assignments have been also been made in other regions of 
the protein. The assignment process for the various CYP101 forms in this project also 
resolved discrepancies or errors in assignments between the two previously published 
data sets. 
The assignment process was started using the published assignments for the 2D 
HSQC-TROSY spectra as a starting point. Since the published data is available only for 
the camphor-bound form, assignments were made for this form first by using the 
published assignments outlying resonances as a reference. Based on similarity of H, N 
and Cα chemical shifts, N-H assignments were transferred from the previous camphor-
bound data set to the current data set where there was sufficient confidence and then 
verified independently via the 3D dataset connectivity, accepted Cα and Cβ chemical 
shifts, and their presence in selective labeled spectra. This independent verification also 
allowed to identify approximately 8 assignments that were erroneous in previous 
publications. A similar strategy was followed to transfer assignments from the camphor-
bound form to other ligand-bound forms as well as the ligand-free form. As seen with 
previously published reduced and oxidized CYP101 spectra, the Cα chemical shifts tend 
to stay within a smaller range than the N and H chemical shifts, which allowed for 
comparison of the 3D datasets and transfer of assignments between the various 
CYP101 forms. Again, where there was difference in chemical shifts observed during 
the transfer process, independent verification as described above was undertaken. 
Based on this assignment process, assignments totaling between 138-152 were 
obtained per CYP101 form (Table 2). This represents an increase of almost 50% 
assignments compared to previously published list and more importantly a majority of 
the resonance assignments in the SRS region which were only partially made in 









Table 2 Summary of 3D NMR experiments on various forms of CYP101 and details 
of resonance assignments available (x indicates experiment performed for a 
certain CYP101 form) 
 Ligand Free Camphor Norcamphor Nicotine Ketoconazole 
HNCA X X  X X 
HNCO X X X X X 
HNCACB X X    
HN(CO)CA X X X X X 
Total N-H 
Assignments 
138 152 139 149 140 
Total SRS N-H 
assignments 
41 48 44 47 42 
 
 
Several of the assignments were already established in previously published 
data sets, but some assignments are novel to this work. Overall, the most assignments 
were obtained for the camphor-bound spectra.  As the camphor-bound form’s chemical 
shifts were used as a reference for assigning the other forms, this represents the 
maximum limit for this dataset. The nicotine-bound form has a similar number of 
assignments to camphor, due to its fairly narrow peaks that allowed good resolution to 
see peak connectivity. Ligand-free, norcamphor-, and ketoconazole-bound form 
assignments suffered from dynamic line-broadening, causing peaks to not appear with 
sufficient intensity in the spectra, thereby losing the connectivities during the 
assignment process. For all ligand-bound and ligand-free forms, new assignments were 
added than present in previous data sets for the F and G helices, FG loop as well as the 
N terminal loop that makes up the bottom lip of the SRS. Additional assignments have 
also been made to the β5 sheet and ends of the B’ helix, making for a thorough 
coverage of the SRS. For regions outside the SRS, higher coverage of assignments has 
been obtained, particularly in the three corner regions of the triangular structure. 
Combined together, this provides adequate coverage of the entire protein to make 
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interpretation of dynamic changes in the various CYP101 forms from both a local and 
global perspective.  
 
3.3 NMR spectra of 15N selectively labeled CYP101 samples 
 
15N selectively labeled CYP101 spectra for different amino acid types were also 
collected to verify and augment the resonance assignments obtained from the 3D NMR 
sequential assignment strategy. This involved preparing the protein samples using a 
single 15N labeled amino acid with the remaining 19 amino acids unlabeled so that the 
2D 1H-15N HSQC-TROSY spectrum will only have the chemical shifts for the labeled 
amino acid visible (Figure 12).  Similar 15N selective labeled spectra were collected for 
all 4 ligand-bound and ligand-free forms of oxidized CYP101 for the following 7 amino 
acids: Alanine, Glycine, Isoleucine, Leucine, Lysine, Phenylalanine, and Valine.  As 
expected, the selectively labeled spectra in all cases contained considerably less 
number of peaks compared to the corresponding uniformly labeled spectra indicating 
that the selective labeling was successful. For 4 of the amino acids labeled - Alanine, 
Lysine, Phenylalanine and Valine, the number of peaks in the selectively labeled 
spectra generally matched the number of amino acids of that amino acid type in the 
amino acid sequence of CYP101. About 4 Alanine, 7 Valine, and 6 Phenylalanine peaks 
were missing due to paramagnetism in every ligand-bound spectra.  The ligand-free, 
ketoconazole-bound and norcamphor-bound spectra showed approximately 3-4 fewer 
peaks than camphor- and nicotine-bound due to broadening from dynamics. However, 
for the remaining 3 amino acid types - Glycine, Leucine and lsoleucine, additional peaks 
were observed in the spectra than were expected, which was the result of scrambling of 
the intended labeled amino acid to other amino acids during protein expression. For 
example, the 15N label on the amino group of Glycine is known to scramble to serine 
and threonine due to shared metabolic pathways which leads to interconversion of 




Figure 12: Comparison of 2D 1H-15N HSQC-TROSY of camphor-bound CYP101 
uniformly labeled (left) and selectively labeled with 15N Lysine (right). Only the 15N 
lysine peaks are seen, identifying some of the peaks in the uniformly labeled 











This actually was useful in our case, since it allowed the analysis of all three 
amino acid types without having to prepare a separate sample for serine and threonine. 
The three amino acid types could be separated based on their unique Cα and Cβ 
chemical shifts. Leucine is known to scramble to both Isoleucine and Valine, however 
since no scrambling as seen in the Valine spectra and very little scrambling seen in the 
isoleucine spectra, the peaks from these spectra were used to identify the peaks for 
leucine. Comparison of the selectively labeled CYP101 spectra with uniformly labeled 
CYP101 spectra allowed for resolution of ambiguities in the 3D spectra, helping in 
assignment of several of the peaks for each amino acid type. There were some peaks 
that remained unassigned for each amino acid type as sequential connectivities could 
not be established for them. However, at least the amino acid type is known for them 







MODELING OF CYP101-KETOCONAZOLE COMPLEX STRUCTURE VIA 
MOLECULAR DOCKING 
 Interpretation of dynamic changes between the various CYP101 forms from a 
functional perspective requires structural information on all forms. Currently, the crystal 
structures of CYP101 in the ligand-free form and 3 out of the 4 ligand-bound forms 
(camphor, norcamphor and nicotine) are available. From the preliminary NMR data, the 
ketoconazole-bound form of CYP101 is found to be fairly flexible and thus is an 
important complex to study in terms of dynamics. However, there is no published 
structure for CYP101 bound to ketoconazole, which limits the dynamic interpretation 
that can be done for this complex. Attempts to crystallize CYP101 bound to 
ketoconazole based on published crystallization conditions for ligand-free and other 
ligand-bound crystal structures of CYP101 have been unsuccessful, preventing 
elucidation of ketoconazole-bound CYP101 structure via Xray crystallography. 
NMR spectroscopy offers another avenue for solving the ketoconazole-bound 
structure, however, can be quite challenging. Traditionally, solution NMR methodology 
has been used to solve de novo structures of proteins and protein complexes that are 
25 kDa in size or below, and CYP101 is ~ 44kDa, well above that limit. This large size 
can broaden spectral linewidths due to decreased molecular tumbling, which makes it 
difficult to collect intermolecular restraints in form of NOEs and residual dipolar 
couplings. In addition, due to the large number of amino acid residues (414) in CYP101, 
there is bound to be significant overlap of resonances because of spectral crowding that 
could interfere with the ability to determine the intermolecular restraints with sufficient 
accuracy. Deuteration of CYP101 can potentially be used to overcome these limitations, 
but at the expense of losing protons in the protein which mainly contribute to the 
intermolecular NOEs. The problem is further compounded by the limited availability of 
resonance assignments for oxidized CYP101 due to paramagnetic effect from the 
heme, especially in the SRS region which can significantly reduce the number of 
intermolecular constraints available for this important region. Based on these 
considerations, utilization of traditional NMR methods to solve the complex structure of 
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ketoconazole-bound CYP101 was not deemed to be deserving of the required effort. 
Instead, use of molecular docking methods was considered to obtain the structure of 
this complex.  
There are several options currently available in terms of molecular docking 
software such as DOCK, ROSETTA, AUTODOCK VINA and HADDOCK to accomplish 
structural modeling of the complex. After test runs of docking using all of these software 
and evaluating the pros and cons, HADDOCK was chosen to enable the docking of the 
complex [62].  There are several advantages of using HADDOCK compared to the other 
docking software. The biggest advantage is that the docking protocol allows use of 
NMR-derived or other forms of direct restraints to facilitate docking of two molecules, 
which is not possible in the other docking software. It also allows use of indirect 
restraints in form of flexible and non-flexible residues allowing flexible docking that 
permits sampling of multiple conformations. An optimal structure can be calculated 
using energy minimization and short molecular dynamics simulation as the final step in 
the procedure. This circumvents the need for having to use a separate molecular 
dynamics program to further equilibrate the docked structures, which would be 
necessary, for example in AUTODOCK VINA. The flexible docking feature is especially 
important for this complex, as preliminary NMR data shows that CYP101 is very flexible, 
especially in the ketoconazole-bound form. Availability of NMR assignments and other 
indirect restraints such as chemical shift perturbations from comparison of 
ketoconazole-bound spectra with ligand-free form spectra, allowed us to define which 
residues can be made flexible and which ones can be kept fixed during the docking, 
which permits a guided docking process for the complex rather than random rigid body 
docking, increasing the probability of obtaining feasible structures for the complex. 
HADDOCK outputs the final docked and equilibrated structures after water refinement 
with a ranking based on calculated energy of favorable interactions and RMSD, which 






4.1 Docking Protocol for the Ketoconazole-CYP101 complex 
 
 The docking of ketoconazole was performed using the ligand-free structure of 
CYP101 published previously (PBD id: 3L62) [40]. The ligand-free structure was chosen 
as the initial structure for docking as NMR chemical shift perturbation data suggested 
that the ketoconazole-bound structure conformation resembled it the closest relative to 
the other ligand-bound CYP101 structures. Since the PDB file for the ligand-free 
structure is missing structural coordinates for the disordered regions such as the B’ helix 
and a N terminal fragment of 10 residues, these regions were rebuilt in the molecular 
operating environment (MOE) software. MOE was also used to calculate the partial 
charges on the protein and do energy minimization after rebuilding of the structure.  As 
a double-check, partial charges were also calculated in Chimera, and no appreciable 
difference in assignment of partial charges was seen between the two programs, 
despite the fact that they use different methods to calculate the charge [63]. The initial 
three-dimensional structure for ketoconazole molecule was generated using 
CHEMDRAW (Figure 13).  Partial charges and hydrogens were added to this structure 
using CHIMERA followed by energy minimization of the structure in MOE. Energy 
parameter and topology files for ketoconazole to be utilized in the docking process were 












With the initial structures for the protein and ligand generated for docking, 
restraints were defined in HADDOCK to bring the structures together in a rigid body 
docking process. Since it is possible in HADDOCK to specify which specific interactions 
the ligand can form with the protein, a restraint of 0.5 Angstroms (with an upper and 
lower bound of 1 Angstroms) between the NB1 nitrogen in imidazole ring of 
ketoconazole structure (Figure 13) and the heme iron was specified based on 
previously available information on the ligating site of ketoconazole with CYP101 in 
other published P450-ketoconazole complex structures [52, 64].  Similar bond formation 
is seen for the other inhibitors such as nicotine when it interacts with CYP101. The 
general binding site for ketoconazole on CYP101 for initial rigid body docking was 
designated as the opening formed by the SRS regions which is known to provide an 
entry channel to the heme active site. The regions in SRS such as the B’ helix and tip of 
the F-G loop were set as fully flexible whereas the semi-flexible interfaces were defined 
as the rest of the FG loop, the F/G/H helices, and part of the β5 sheet (380-400), based 
on the NMR chemical shift perturbations observed between the ketoconazole-bound 
and ligand free spectra. Other minimal loose distant restraints were defined for the 
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flexible branched ring structures of ketoconazole to guide the structure into the binding 
pocket since the unconstrained rings in initial docking runs were observed to generate 
steric clashes with the residues in binding pocket. These included a restraint of 3 
Angstroms from the chlorinated ring of ketoconazole to Phe98 and Phe193, and from 
the oxygen on the longer chain to Lys392 and Ser393 and were equally weighted for the 
docking run. These restraints were defined based on similar interactions of 
ketoconazole rings with the protein observed in the same general location as deduced 
from previous P450-ketoconazole complexes [51, 65, 66]. Energy parameters and 
topology for the protein were generated by HADDOCK during the docking process.  The 
docking was performed on a local Linux server and took approximately 20 hrs per run 









For each run, 1000 structures were generated during rigid body docking, and 200 
of these structures were chosen based on HADDOCK’s automated scoring system for 
refinement in the annealing phase where the rest of the protein was allowed to be semi-
flexible.  All 200 structures then underwent explicit solvent refinement and water 
refinement, following which the structures were then ranked based on RMSD 
comparison, energy analysis, and restraint violations, as well as other factors, and the 
lowest energy ranked structure was chosen as the representative structure and further 
analyzed. 
This lowest energy structure has the imidazole nitrogen in ketoconazole 
coordinated to the iron in the heme group as expected (Figure 15). The ketoconazole 
ligand orientation within the binding pocket of CYP101 was reproduced well in a way 
that’s both consistent with the NMR data as well as other published ketoconazole 
structures with the chlorinated phenyl ring generally oriented towards the B’ helix and 
sits in a hydrophobic pocket defined by Tyr96, Phe98 and Phe193 (Figure 16) The 
longer chain of ketoconazole orients in the opposite direction and is positioned in a 
pocket between the β5 and FG loop making very weak contacts with the basic side-
chains from the B’ helix and β5 loop via the oxygen and nitrogen atoms in the long 
chain. Apart from the lowest energy structure, several other structures with similar or 
slightly increased free energies generated during the run that are generally clustered 
around this lowest energy structure in the binding pocket of CYP101. The chlorinated 
phenyl ring and the longer chain were found to have various flipped orientations for the 
phenyl rings with slight displacement about the lowest energy structure. This ensemble 
of structures is generally consistent with the weak nature of interactions expected 
between the protein and ketoconazole ligand that has a predominant hydrophobic 










Figure 16: Structural view of docking site of ketoconazole in the SRS of CYP101, 
showing the interactions of chlorinated phenyl ring and long chain with specific 
residues in CYP101 
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Overall and residue-wise RMSD for the protein part was calculated between the 
ligand-free and lowest energy docked structure. The residue-wise RMSD is shown in a 
color-coded manner in Figure 17 and when compared to the NMR chemical shift 
perturbations for corresponding residues in the protein color-coded in a similar manner, 
show a good match between the two representations, lending confidence in the docked 
structure produced by HADDOCK. There are no major changes observed in protein 
structure outside of SRS as expected based on these regions not defined as flexible in 
HADDOCK and in line with the minimal NMR chemical shift perturbations for most 
protein regions outside of the SRS. The SRS on the other hand, shows large structural 
deviations in the new docked structure relative to the ligand-free structure, which is 
again in line from the large NMR chemical shift perturbations observed for these 
regions, especially the B’ helix. This indicates that the docked structure of the complex 
reproduces characteristics seen in NMR data fairly well and can be used as a good 












Figure 17: Comparison of NMR chemical shift perturbations between ligand-free 
and ketoconazole-bound CYP101 (left) and RMSD between ligand-free and 
docked ketoconazole-bound CYP101 structure (right).  Color code for Chemical 






















HYDROGEN-DEUTERIUM EXCHANGE EXPERIMENTS TO MONITOR 
LIGAND-DEPENDENT DYNAMIC CHANGES IN CYP101 
5.1 Ligand-dependent dynamic changes in CYP101 from preliminary 2D NMR 
spectra 
 
The 2D 1H-15N correlation spectra for each ligand at saturating levels with 
CYP101 reveals a different pattern of dynamics when compared to the other ligands. 
This can be visualized by looking at the changes in overall peak patterns (Figure 7, 8). 
Comparing the camphor-bound spectrum to the ligand-free spectrum, the peaks in 
ligand-free spectra are generally broader and show multiple peak splittings for several 
resonances in the spectra, which is not observed for the camphor-bound spectrum. This 
indicates that the protein has increased differential dynamics and is sampling more 
conformations in the absence of a ligand than when bound to camphor. This difference 
becomes even more pronounced when comparing the ligand-free spectrum to nicotine-
bound spectrum. The nicotine-bound spectrum shows presence of sharp, similar 
intensity single peak patterns throughout the spectrum with very noticeable peak 
splittings for the vast majority of peaks indicating that the protein overall does not 
sample multiple conformations and is not as dynamic in presence of nicotine (Figure 
18). The norcamphor-bound spectrum, on the other hand, shows an intermediate 
pattern, more dynamic than camphor or nicotine, but also not as dynamic as ligand-free 
or ketoconazole-bound spectra. The ketoconazole-bound spectrum looks most similar 
to the ligand-free spectrum and shows similar increased dynamics throughout the 
protein. These findings are surprising when considering ligand properties.  For example, 
ketoconazole is a large size ligand with several polar groups and would be expected to 
bind the protein with multiple ligand-protein contacts based on its high affinity to  
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Figure 18: Zoomed in portions of 2D 1H-15N HSQC-TROSY of CYP101 in ligand-
free and various ligand-bound forms, showing the different peak patterns in 
terms of chemical shift changes, line-broadening and peak splittings. The amino 
acid G189 in CYP101 is used as an example to illustrate these variations 
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CYP101, locking the protein down to a reduced set of dynamic conformations compared 
to ligand-free form. However, the opposite is observed where the dynamic pattern and 
number of conformations stays comparable to the ligand-free protein, in contrast to any 
of the other ligands examined. Similar discrepancy is observed in the case of nicotine, 
which is a small ligand. One would expect the ligand to not make any significant protein-
ligand contacts given its size and allow the protein to freely sample multiple 
conformational states. However, the affinity of nicotine is surprisingly high and most of it 
is derived by directly coordinating with the heme. In spite of this, the ligand still reduces 
dynamics throughout the protein and is the least dynamic of all the ligand-bound forms 
examined here. 
 The main conclusion from the above observations is that dynamics for CYP101 
can vary depending on which ligand is present, and not necessarily in the expected 
manner, with some inducing greater dynamic changes and some smaller.  This is in 
contrast with how superimposable the camphor-, nicotine-, and norcamphor-bound 
crystal structures are, indicating that the crystal structures are not able to capture the 
multitude of conformations the protein can undergo when in solution. Although there are 
small differences observed in these structures in the SRS regions, virtually no structural 
or dynamic differences are detected in regions outside of SRS, which has led to the 
longstanding notion that only the structural flexibility of the SRS determines binding of a 
particular ligand. This is not supported by our NMR observations that the protein as a 
whole, responds to the binding of a ligand and this event leads to significant dynamic 
differences throughout the protein. A detailed investigation of ligand-dependent 
dynamics of CYP101 by solution NMR can help resolve the question as to what the 
basis of the dynamic differences observed in the NMR spectra with various ligands is 
and which regions are responsible for these dynamics. This is particularly important in 
light of previous observations that fast collective motions span the entire protein in 
CYP101, including regions remote from the SRS, and facilitate ligand binding via 
translating into slower motions[47]. However, this was demonstrated only for one ligand 
and it is not clear if recognition of other ligands follows a similar mechanism or is 
timescale dependent. An important first step would be to characterize the dynamic 
changes with different ligands and whether there is a distinct pattern for each ligand on 
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different timescales that would indicate whether only the SRS or the entire protein 
responds to the binding event. 
 There are different NMR experiments to characterize motions on different 
timescales. While the 2D 1H-15N NMR spectra indicate the presence of dynamic motions 
on all timescales, these only serve as a qualitative measure of protein dynamics that 
appear in a combined manner in these 2D spectra and the motions on different 
timescales need to be characterized separately to figure out which type of motions 
contribute to what extent to the dynamics of a protein. Motions on the slower timescales 
(s-min) are the easiest to characterize and utilize measurement of amide exchange 
rates that monitor slower breathing motions of the protein. These experiments require 
exchange of amide protons with deuterium and the determination of these exchange 
rates in a residue-dependent manner allows interpretation of opening and closing 
motions of the protein especially water access channels, facilitating exchange of interior 
amide protons. These motions not only report on the overall global flexibility of the 
protein but also report on motional changes in key residues in local regions of the 
protein. The global motions are usually linked to local functional motions of the protein 
in terms of a dynamic hierarchy, which permits drawing inference about some of the 
faster motions and coordination between different regions of the protein in facilitating 
ligand binding [3]. Dynamic differences in hydrogen exchange patterns also indicate 
rearrangement of hydrogen bonding patterns and different solvent exposure of protein 
areas, suggesting a likely role for water molecules in dynamics and thermodynamics of 
ligand binding. With these goals in mind, backbone amide exchange measurements 
were carried out for the ligand-free and 4 ligand-bound forms of CYP101 to map the 
dynamic differences in CYP101 on slow dynamic timescales in a ligand-dependent 
manner. 
5.2  Measurement of Amide Exchange Rates for Various Forms of CYP101  
 
 Amide exchange (HDX) experiments can be used to quantify the slow time scale 
motions of the protein by measuring the peak intensities of backbone amide protons in a 
2D 1H-15N correlation spectrum as a function of time when exposed to D2O. In this 
experiment, the fully protonated lyophilized protein is dissolved in D2O and the rate of 
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exchange of amide protons with deuterium is monitored over a period of time (Figure 
19). The protons attached to carbon are not exchangeable due to the nonpolarity of the 
bond and thus their exchange rates cannot be measured. The amide protons exchange 
differentially based on various factors with the main ones being presence of hydrogen-
bonding and increased or decreased dynamic motions which leads to different solvent 
exposure. This causes the peaks corresponding to these amide protons in the 2D 
spectrum to rapidly or slowly decrease in intensity at different rates. Identical 2D spectra 
can be measured at different time intervals from which peak intensities can be extracted 







Figure 19: Scheme for Hydrogen-Deuterium Exchange experiment [67] 
 
 
Depending on their exchange rates, the resonances can be categorized into three 
different groups:  Fast, intermediate, or slow exchange.  Fast exchange is typically 
designated by comparing the reference time point with no D2O added to the time point 
at the end of the first collected spectrum. If the resonance has disappeared from the 
spectrum by that time point, it is considered to undergo fast exchange.  In this case, the 
timepoint of the end of the first collected spectrum corresponded to approximately 28 
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minutes. Spectra were collected every 28 minutes defining the time interval of the 
timepoints. A resonance was considered to be undergoing intermediate exchange if it 
was visible after 28 minutes but not after approximately 16 hours and undergoing slow 
exchange if it remained visible after the 16th hour up to the final time point collected 
around 40 hours. 2D 1H-15N spectra for all 5 forms of CYP101 were acquired in an 
identical manner at identical time intervals and total time periods.                                      
Cross-peak intensities and volumes in each spectra for all the assigned and 
visible peaks were measured with a standard integration routine in NMRViewJ and their 
time-course was fitted to equations 1 and 2 to calculate exchange rates as a function of 
time. 
ln I = ln Io - Rext                                                   Eqn. 3 
ln V0 = ln V0 - Rext                                               Eqn. 4 
where I and V is the peak intensity, I0 and V0 is the initial peak intensity, Rex is the 





Figure 20: 2D 1H-15N HSQC spectra of CYP101 bound to various ligands showing 
amide exchange at different timepoints starting with no D2O added at 0 hrs to 40 





Table 3. HDX exchange categorization table (Actual exchange rate constants are 




Camphor Nicotine Ligand Free Ketoconazole Norcamphor 
LEU 11 N term Loop Fast Slow Slow Intermediate Slow 
ALA 12 N term Loop  Fast Fast Fast Fast 
HIS 17 N term Loop Fast Fast Fast Fast Fast 
VAL 18 N term Loop Intermediate Intermediate Intermediate Intermediate Intermediate 
LEU 22 N term Loop Slow Slow Intermediate Fast -- 
VAL 23 N term Loop Slow Slow Intermediate Slow Slow 
PHE 24 N term Loop Slow Slow Intermediate Slow Slow 
PHE 26 N term Loop Fast Slow Fast Fast Intermediate 
ASP 27 N term Loop -- Fast Fast Fast Fast 
TYR 29 N term Loop Slow Slow Fast Slow Slow 
ASN 30 N term Loop Intermediate Intermediate Intermediate Intermediate Intermediate 
ALA 36 N term Loop Fast Fast Fast Intermediate Fast 
GLY 37 A Helix Slow Slow Fast Intermediate Fast 
ASN 49 Aβ1 Loop Fast Slow Slow Slow Slow 
VAL 50 Aβ1 Loop Intermediate Slow Intermediate Intermediate Fast 
VAL 54 β1 Sheet Slow Slow Intermediate Slow Slow 
TRP 55 β1 Sheet Slow Slow Intermediate Intermediate Slow 
THR 56 β1 Sheet Slow Slow Intermediate Intermediate Slow 
CYS 58 β1 Sheet Slow Fast Slow Intermediate Slow 
ASN 59 β1 Sheet Intermediate Fast Fast Fast Fast 
GLY 60 β1 Sheet Fast Fast Fast Fast Fast 
GLY 61 β1 Sheet Slow Slow Intermediate Intermediate Slow 
HIS 62 β1 Sheet Slow Slow Intermediate Slow Slow 
ILE 64 β1 Sheet Slow Slow Intermediate Slow Slow 
ALA 65 β1 Sheet Slow Slow Intermediate Intermediate Slow 
THR 66 β1 Sheet Slow Slow Intermediate Slow Slow 
ARG 67 B Helix Slow Slow Intermediate Intermediate Slow 
GLY 68 B Helix Fast Fast Fast Fast Fast 
GLN 69 B Helix Slow Slow Intermediate Intermediate Fast 
LEU 70 B Helix Fast Fast Fast Fast Fast 
CYS 85 BB' Loop Slow Slow Slow Fast Slow 
PHE 87 BB' Loop Intermediate Slow -- -- Fast 
ILE 88 BB' Loop Fast Slow -- -- -- 
ARG 90 B' Helix Intermediate Fast Fast Fast Fast 
GLU 91 B' Helix Fast Fast Fast -- Fast 
ALA 92 B' Helix Fast Intermediate -- -- Intermediate 
GLY 93 B' Helix Fast Fast Fast Fast Fast 
GLU 94 B' Helix Slow Slow Slow Slow Slow 
ALA 95 B' Helix Fast Fast Intermediate Fast Intermediate 
TYR 96 B' Helix Intermediate Fast Fast Fast Fast 
PHE 98 B'C Loop Fast Slow -- -- -- 
VAL 123 C Helix Slow Slow Intermediate Fast Slow 
VAL 124 C Helix Fast Slow Fast Intermediate Slow 
ASP 125 C Helix Fast Slow -- Intermediate Slow 
LYS 126 C Helix Slow Fast Intermediate Intermediate Slow 
SER 141 D Helix Intermediate -- Fast Fast Fast 
GLN 145 D Helix Intermediate Fast Intermediate Slow Intermediate 
GLY 146 DE Loop Intermediate Intermediate Intermediate Intermediate Intermediate 
GLN 147 DE Loop Slow Slow Slow Slow Intermediate 
CYS 148 DE Loop Slow Slow Slow Slow Slow 
ASN 149 E Helix Fast Fast Intermediate Intermediate Fast 
PHE 150 E Helix Intermediate Intermediate Intermediate Intermediate Intermediate 
THR 151 E Helix Fast Fast Intermediate Intermediate Intermediate 
GLU 152 E Helix Fast Intermediate Intermediate -- -- 
ASP 153 E Helix Slow Slow Slow Slow Slow 
LEU 165 E Helix Slow -- Intermediate Slow -- 
LEU 166 E Helix Slow Fast -- Fast -- 
ALA 167 E Helix Slow Slow Intermediate Slow Slow 
GLY 168 E Helix Intermediate Intermediate Intermediate Intermediate Fast 
GLU 171 EF Loop Fast Fast Fast Intermediate Slow 
GLU 172 EF Loop Fast Fast Fast Intermediate Fast 
LYS 178 F Helix Slow Fast Intermediate Intermediate Intermediate 
TYR 179 F Helix Intermediate Intermediate -- -- Intermediate 
THR 185 F Helix Slow Slow Intermediate Fast Fast 






Table 3 continued 
GLY 189 FG Loop Intermediate Fast Intermediate Fast Fast 
SER 190 FG Loop Fast Slow Slow Intermediate Slow 
MET 191 FG Loop Fast Slow Fast Slow Slow 
THR 192 G Helix Intermediate Intermediate Fast Intermediate Slow 
PHE 193 G Helix Fast Fast -- -- Slow 
ALA 194 G Helix Intermediate Slow Intermediate Fast Fast 
LYS 197 G Helix Slow Slow -- Intermediate -- 
GLU 198 G Helix Slow Slow Intermediate Slow Fast 
ALA 199 G Helix Slow Slow Fast Fast Fast 
LEU 200 G Helix Slow Slow Intermediate Intermediate Slow 
ILE 207 G Helix Fast Intermediate Intermediate Intermediate Intermediate 
ILE 208 G Helix Slow Slow Slow Slow Slow 
LYS 214 G Helix Slow Slow Fast Intermediate Intermediate 
GLY 216 GH Loop Fast Fast Fast Fast Fast 
ALA 219 H Helix Slow Slow -- -- -- 
ILE 220 H Helix Slow Slow Fast Fast Fast 
VAL 223 H Helix Slow Slow Intermediate Intermediate Slow 
ALA 224 H Helix Slow Slow Intermediate Intermediate Fast 
ASN 225 H Helix Intermediate -- -- -- Fast 
GLY 226 β2 Sheet Intermediate Intermediate Intermediate Fast Intermediate 
GLN 227 β2 Sheet Intermediate Slow Intermediate Slow Slow 
VAL 228 β2 Sheet Intermediate Intermediate Fast Fast Intermediate 
ASN 229 β2 Sheet Slow Slow -- -- -- 
GLY 230 β2 Sheet Fast Fast Intermediate Fast Fast 
ARG 231 β2 Sheet Slow Slow Slow Slow Slow 
ILE 233 β2 Sheet Intermediate Intermediate Intermediate Fast Intermediate 
THR 234 I Helix Intermediate Slow Intermediate Fast Fast 
ALA 265 I Helix Slow Fast Slow Intermediate Slow 
LYS 266 I Helix Fast Slow Intermediate Slow Slow 
SER 267 I Helix Intermediate Slow Slow Slow Slow 
ARG 271 J Helix Slow Fast Slow Slow Slow 
GLN 272 J Helix Slow Intermediate Slow Slow Intermediate 
GLU 273 J Helix Fast Fast Fast Fast Slow 
LEU 274 J Helix Intermediate Slow Intermediate Slow Slow 
GLU 279 JK Loop Fast Fast Fast Fast Fast 
ARG 280 K Helix Intermediate Intermediate Intermediate Slow Intermediate 
ASP 304 β3β4 Loop Intermediate Fast Slow Intermediate Fast 
TYR 305 β4 Sheet Slow Slow Intermediate Intermediate Fast 
GLU 306 β4 Sheet Fast Fast Fast Fast Fast 
PHE 307 β4 Sheet Slow Intermediate Intermediate Intermediate Slow 
HIS 308 β4 Sheet Fast Fast Fast Fast Slow 
GLY 309 β4 Sheet Fast Slow Fast Fast Fast 
VAL 310 β4 Sheet Slow Slow Intermediate Intermediate Slow 
GLN 311 β4 Sheet Slow Intermediate Intermediate Fast Slow 
LEU 312 β4 Sheet Slow Slow Intermediate Intermediate Slow 
LYS 313 β3β4 Loop Slow Slow Intermediate -- Slow 
LYS 314 β3β4 Loop Slow Slow Intermediate Slow Slow 
GLY 315 β3 Sheet Fast Fast Intermediate Fast Fast 
ASP 316 β3 Sheet Slow Slow Intermediate Slow Slow 
GLN 317 β3 Sheet Intermediate Intermediate Fast Fast Intermediate 
LEU 319 β3 Sheet Slow Slow Fast Intermediate Slow 
LEU 320 β3 Sheet Slow Slow Intermediate Slow Slow 
ALA 333 β3L loop Fast Fast Slow Fast Slow 
MET 336 β3L loop Fast Fast Intermediate Intermediate Intermediate 
HIS 337 β3L loop Slow Fast Fast Fast Fast 
VAL 338 β3L loop Slow Fast Intermediate Fast Fast 
ASP 339 β3L loop Intermediate Intermediate Intermediate Intermediate Intermediate 
PHE 340 β3L loop Fast Fast Fast Fast Fast 
SER 341 β3L loop Fast Fast Intermediate Intermediate Fast 
ARG 342 β3L loop Fast Intermediate Intermediate Fast Intermediate 
VAL 369 L Helix Fast Intermediate Fast Fast Fast 
LYS 372 L Helix Slow Slow Slow Fast Fast 
ASP 380 Lβ5 Loop Intermediate Intermediate Intermediate Slow Intermediate 
PHE 381 Lβ5 Loop -- Fast Intermediate Intermediate Intermediate 
SER 382 β5 Sheet Slow Slow Slow Slow Slow 
ILE 383 β5 Sheet Slow Slow Slow Slow Intermediate 
ALA 384 β5 Sheet Intermediate Intermediate Intermediate Intermediate Intermediate 
GLY 386 β5 Sheet Fast Slow Fast Fast Fast 
ALA 387 β5 Sheet Fast Intermediate Intermediate Fast Fast 
GLN 388 β5 Sheet Intermediate Intermediate Fast Slow Intermediate 






Table 3 continued 
GLN 390 β5 Sheet Fast Fast Fast Fast Fast 
HIS 391 β5 Sheet Fast Fast Fast Fast Fast 
LYS 392 β5 Sheet Fast Slow Intermediate Slow Slow 
SER 393 β5 Sheet Slow Slow Intermediate Slow Intermediate 
GLY 394 β5 Sheet Slow Slow Intermediate Intermediate Intermediate 
VAL 396 β5 Sheet Intermediate Intermediate -- -- -- 
GLY 398 β5 Sheet Slow Slow Intermediate Intermediate Intermediate 
VAL 399 β5 Sheet Intermediate Fast -- -- -- 
GLN 400 β5 Sheet Slow Slow Slow Slow Slow 
ALA 401 β5 Sheet Intermediate Fast -- Slow Fast 
LEU 402 β5 Sheet Slow Slow Slow Slow Slow 
VAL 405 β5 Sheet Slow Slow Slow Slow Slow 
ALA 409 C term Loop Slow Fast Intermediate Slow Slow 
THR 410 C term Loop Fast Fast Fast Fast Fast 
LYS 412 C term Loop Fast Slow Slow Fast Slow 
ALA 413 C term Loop Fast Slow Slow Intermediate Fast 
VAL 414 C term Loop Fast Fast Slow Intermediate Fast 
 
 
Total 152 149 138 139 140 
 Fast 50 38 40 49 51 
Intermediate 36 37 72 50 31 




5.3 Ligand-dependent dynamic changes in the substrate recognition regions of 
the protein structure 
 
 
The amide exchange experiments show that there are significant differences in 
overall slow timescale dynamics of the protein in a ligand dependent manner (Figure 
20). Comparing the endpoint of the exchange process for various CYP101 forms after 
40 hours of D2O exposure, it is clear that the number of resonances remaining in the 
spectra varies greatly based on the ligand. The nicotine-bound protein spectrum shows 
the largest number of peaks remaining after 40 hours followed closely by camphor-
bound protein, indicating an overall slower exchange pattern compared to the other 
forms. A large fraction of the peaks (~50%) are still visible after 40 hrs of exchange. 
This is in contrast to the camphor-, ligand-free, ketoconazole- or norcamphor-bound 
spectra, which only have approximately 20-40% of the resonances still visible 
depending on the ligand. The intermediate exchange regime follows a similar trend with 
only about 25% of peaks showing intermediate exchange for nicotine, camphor and 
norcamphor, whereas the other forms show a much higher percentage (40-50%) of 
intermediate exchange. All CYP101 forms show a similar fast exchange trend with 
between 25-35% of the peaks undergoing fast exchange indicating that the fast 








Camphor Nicotine Ligand 
Free 
Ketoconazole Norcamphor  
Fast 32% 25% 28% 35% 36% 
Intermediate 25% 25% 52% 36% 28% 




While these exchange percentages were determined considering the protein as a 
whole, when the exchange patterns are considered region-wise such as those for SRS 
for example, there are considerable differences between the various CYP101 forms 
(Figure 21). While the exchange patterns are largely similar for the B’ helix in all 
CYP101 forms ranging from intermediate to fast exchange, the F-G loop/helices and the 
 5 sheet show considerable differences. The similar exchange pattern for the B’ helix is 
not surprising since the helix is mostly solvent exposed and although the crystal 
structures point to more disorder in the ligand-free form than the camphor-, 
norcamphor- and nicotine-bound forms where the helix stays largely ordered, the 
increased exposure to solvent predisposes this helical region to intermediate to fast 
exchange. Thus, no specific inferences can be made from exchange patterns in this 
region although it is one of the most dynamical regions of the protein. The region 
preceding the B’ Helix (residues 80-90), which is shielded somewhat better from the 
solvent compared to the helix itself, however, can give some insights in the helix’s 
dynamics. Comparison of exchange patterns in this region shows that the while mostly 
slow exchange is observed for this region in the nicotine-bound form, a combination of 
fast and intermediate exchange is observed for the camphor-bound and norcamphor-
bound forms, whereas predominantly fast exchange is observed for the ketoconazole-
bound and ligand-free forms. This suggests that the B’ helix is likely more dynamic in 
forms like ketoconazole-bound and ligand-free CYP101, which is in line with the major 
chemical shift perturbations and more dynamic peak pattern changes from 2D NMR 




Figure 21: Comparison of the SRS amide exchange patterns for the various 
CYP101 forms on the same structure (2CPP) (top) and on their various 
crystal/docked structures (bottom) 
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The F-G loop formed as an intervening segment by the F and G helices is one of 
the most flexible regions in all P450s and is known to adapt to presence of different 
ligands in the binding pocket by changing conformations based on the numerous crystal 
structures published for different P450s so far. In CYP101, the F-G loop is observed to 
move by as much as 9-10 Angstroms distance to convert between the open (ligand-
free) and closed (ligand-bound) conformations upon binding of certain ligands such as 
camphor and nicotine with slightly smaller displacement for norcamphor. The exchange 
pattern for the F-G loop matches this conformational tendency in the crystal structures 
where the loop exhibits predominantly slow exchange in the nicotine-bound form, while 
in the camphor- and norcamphor-bound forms the loop exhibits a mix of slow and 
intermediate exchange. In contrast, the F-G loop in ligand-free form is observed mostly 
as intermediate exchange, which suggests it is sampling between the open and closed 
forms as has been suggested from previous structural and dynamic studies[68]. The 
most surprising pattern of dynamics for this loop is from the ketoconazole-bound form, 
which shows it as a mix of slow and intermediate exchange. This is likely due to the fact 
that the placement of the bulky ligand such as ketoconazole in the binding pocket 
hinders solvent access to this region. This would also explain the mostly open 
conformation of F-G loop in the ketoconazole-bound form since it is unable to move 
freely down to wrap around and close the binding pocket like it does in case of other 
ligands, which makes it less flexible relative to ligand-free form even though it is an 
open conformation like the ligand-free form. 
Like the F-G loop, the F and G helices themselves also play a role in binding of 
ligands as they move in tandem with the loop. The regions of the helix close to the F-G 
loop show predominantly slow exchange for the nicotine-bound form matching what is 
observed for the F-G loop. The camphor-bound form shows a mix of slow and 
intermediate exchange for the helices, implying it is more dynamic than the nicotine-
bound form, but still favoring the closed conformation. The norcamphor-bound form is 
even more dynamic with the helices showing mostly intermediate exchange. In contrast, 
the ligand-free form shows a mix of intermediate and fast exchange which matches 
what is seen for the F-G loop. The ketoconazole-bound form exhibits the highest 
dynamics of all the forms with mostly fast exchange for the F helix and a mix of slow, 
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intermediate and fast exchange for the G helix. This suggests that the F and G helices 
are moving more rapidly in the ketoconazole form in tandem with the F-G loop even 
though they are bound to a large ligand. Based on the docked model structure for the 
CYP101-ketoconazole complex, the F-G loop does not dip far down to make any 
interactions with the ligand, but the sidechain of Phe193 is part of the hydrophobic 
pocket formed by several aromatic rings that surrounds the chlorinated phenyl ring and 
thus restricts the motion of the G helix partially, explaining the dynamic behavior of this 
helix.    
The β5 region (381-404) largely shows a mix of exchange patterns for all 
CYP101 forms. The nicotine-bound protein shows the slowest exchange of all forms 
followed closely by the camphor-bound whereas the ligand-free, ketoconazole and 
norcamphor-bound forms show higher rates of exchange. Like the F-G loop, this region 
of the SRS is also known to undergo a conformational change contributing to the switch 
from the open to closed conformation upon ligand binding. Since the protein is observed 
predominantly in the closed conformation for nicotine-bound and camphor-bound forms, 
solvent access is likely restricted to this region in these forms explaining the observed 
slow exchange. In contrast, the ligand-free, norcamphor-bound and the ketoconazole-
bound forms sample more of the open conformations allowing better solvent access and 
hence more intermediate to fast exchange is observed for these forms. 
Finally, the last flexible region of the SRS is a short segment of the N-terminal 
loop (25-31) which lies at the bottom of the binding pocket. This region also shows 
variable amide exchange properties depending on the ligand. The exchange in this 
region is slowest for the nicotine-bound form of the protein but is mostly intermediate for 
the norcamphor and camphor-bound forms, whereas fast exchange is observed 
primarily for the ketoconazole-bound and ligand-free forms of the protein. This is in line 
with what is seen for the other regions of the SRS, where restriction to solvent access 
due to being more in closed conformation versus an open conformation will lead to the 
observed changes for the specific forms. 
In summary, the SRS is most dynamic in the ligand-free, ketoconazole-bound, 
followed by the norcamphor-bound form which is less dynamic, while the camphor-
bound and nicotine-bound forms show the slowest dynamics.  This points to the 
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presence of differential dynamics within these regions depending on the ligand that may 
have an important role in how CYP101 is able to recognize diverse ligands, and it will 
be interesting to see if a similar pattern can be seen in the fast timescales as well. 
 
5.4 Amide Exchange results show ligand-dependent dynamic changes in the 
regions not associated with ligand binding  
 
While there are considerable dynamic differences observed for the flexible SRS 
regions, what is surprising is that noticeable ligand-dependent dynamic differences 
between the various forms are also observed for regions outside of the SRS (Figure 
22). In particular, the C helix shows different dynamics between the various forms with 
nicotine-bound form again showing the slowest exchange followed closely by camphor-
bound form whereas the ligand-free, norcamphor-bound and ketoconazole-bound forms 
showing more a mix of slow, fast and intermediate exchange.  The redox partner of 
CYP101, Pdx, is known to bind to this region and has a structural effect on CYP101 
upon binding. Pdx binding forces CYP101 into a more open conformation than when 
bound to camphor, so it makes sense that the dynamics would also be modulated for 
this region [69].  
The I helix also shows differences in dynamics in a ligand-dependent manner.  
This is the helix that contains the active site residues around the heme and NMR 
resonances can only be observed for monitoring of dynamics on the edges of the helix 
due to the proximity to the paramagnetic heme. The two sides of the helix show 
opposite trends in exchange patterns with nicotine- and camphor-bound forms showing 
slow to intermediate exchange whereas norcamphor-bound, ligand-free and 
ketoconazole-bound forms showing intermediate exchange to fast exchange on one 
side (residues 233-240) which then reverses on the other side (residues 260-268) with 





Figure 22: Comparison of the overall amide exchange patterns for the various 
CYP101 forms on the same structure (2CPP) (top) and on their various 




their exchange rates. The β2 sheet, which leads into the I helix, doesn’t show any major 
changes between ligands. This indicates that the I helix responds differently to different 
ligands, which might be due to different buckling of the structure in the middle kink 
portion of the helix as a response to different ligands that would cause the dynamics at 
the ends of the helix to change. 
Another interesting region that shows dynamic differences based on the ligand is 
the C terminus, which makes up the top right corner of the protein. Surprisingly, fast 
exchange is observed for this region for the camphor-bound form, but slow exchange is 
observed in the ligand-free protein, a reversal of the usual trend. The trends for the 
nicotine-bound, ketoconazole-bound and norcamphor-bound forms still stay the same 
though as observed for the other regions. The region for this is not clear, but it is 
possible that binding of different ligands changes the structure for this region in different 
ways relative to the ligand-free form, which is then reflected also in the change in 
dynamics for these forms. 
Other regions of the protein such as the E helix, J helix and the loops in the 
protein leading in to and out of some of the important secondary structure elements in 
the protein show no significant changes between ligand free and the ligand bound 
forms.  They all show an exchange pattern comprised of a mix of fast and slow 
exchange similar to the ligand-free form, implying that the dynamics in these regions do 
not contribute significantly to ligand binding.  One notable exception is the loop region 
between the G and H helices on the top left corner of the structure which interestingly 
shows slow exchange for nicotine-bound and camphor-bound forms but remains as 
intermediate to fast exchange for the other forms. Recent studies with camphor-bound 
form has shown that this region might provide a second weak binding site for camphor 
[69] which would restrict the dynamics and solvent access for this region leading to the 
observation of slow exchange. There is no evidence currently of nicotine also binding to 
this secondary site, but the exchange could be slow for the nicotine-bound form 
generally in line with other regions of the protein even without binding. The other 
ligands, norcamphor and ketoconazole are likely not binding to this site as well on the 
basis of their exchange rates. 
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 The dynamic differences observed for regions outside the SRS suggests 
that the dynamics of these regions may help modulate substrate binding as well, 
something which was suggested by a recent study using quasielastic neutron scattering 
experiments, which indicated opening and closing motions of the substrate access 
channel that are controlled by correlated interdomain motions of regions away from the 
access channel [47]. These domain motions have their basis in fast, collective motions 
that pervade throughout the protein and the slower timescale motions characterized by 
the amide exchange process may be a manifestation of these. If the fast, collective 
motions do indeed change depending on the ligand, they would be reflected in dynamic 
differences in the exchange rates of these regions and would explain the role of 
dynamics in facilitating ligand access to the active site. This is an intriguing possibility 
and it remains to be seen whether similar trends hold on a region-wise basis even on 
other timescales. If so, that would support our hypothesis of dynamic-modulated ligand 



















CHAPTER SIX: THERMODYNAMICS OF CYP101-LIGAND 
INTERACTIONS 
The dynamic differences observed in different CYP101 forms indicates that the 
mode of interaction of each ligand with the protein is different and may require distinct 
protein-ligand contacts to achieve the required affinity. All ligands, except norcamphor, 
display similar high affinity for CYP101 however are very different in their physico-
chemical properties. Thus, the thermodynamic basis of binding may be rooted in the 
distinct nature of protein-ligand contacts. It would be interesting to investigate whether 
protein dynamics contributes to the binding and whether there is any thermodynamic 
benefit to modulating the dynamics of CYP101.  
The enthalpic (ΔH) and entropic (ΔS) components of the free energy of binding 
(ΔG) can be quite informative in elucidating the driving force for protein-ligand 
interactions. A robust way of determining these components in protein-ligand binding is 
isothermal calorimetry (ITC). ITC measures the heat input or output of a binding 
reaction at a constant temperature by titrating the protein with ligand, giving a direct and 
accurate value for the ΔH of the association. ΔG can be found independently by fitting 
the titration curve which gives the affinity and stoichiometry of binding. ΔS can then be 
calculated from the Gibbs equation at that temperature giving a full thermodynamic 
representation of the system. ITC measurements were carried out for the various 
CYP101-ligand forms in order to understand the thermodynamic driving force for 
association of these ligands with oxidized CYP101 and the role of protein dynamics in 
this process. 
6.1 Isothermal Calorimetry of CYP101-ligand complexes 
 
Titration experiments were carried out for the protein with all 4 ligands as part of 
an ITC setup to calculate the ΔH, binding affinity and ΔS for each protein-ligand 
association. The ITC experiments were performed on a Malvern MicroCal VP-ITC 
instrument. Ligands (camphor, nicotine and norcamphor) were prepared as stock 
solutions in filtered potassium phosphate buffer and were diluted appropriately in the 
same buffer as protein to ensure complete saturation of the protein based on the 
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expected binding affinity (Table 5).  A reverse titration of ketoconazole was carried out 
with the protein, since ketoconazole tends to aggregate at high concentrations. A stock 
solution of ketoconazole in DMSO solvent was initially made and then this stock 
ketoconazole solution was diluted in buffer to reach the appropriate concentration 
(Table 5) which contained only 1% DMSO in the end. Both ligand and protein samples 
were filtered and degassed prior to the experiment. The cell and syringe were both 
thoroughly cleaned and rinsed with filtered and degassed buffer to ensure no solvent 










Kd Δ G Δ H TΔS 
Cam .03 .5 1.98 uM +/- 1.12 -7.72 -2.72 +/- 0.28 -4.96 
Norcam .04 1 176 uM +/- 120 -5.10 +0.69 +/- 0.6 -5.79 
Nico .02 .1 .156 uM +/- 0.1 -9.25 -11.95 +/- 0.5 +2.70 
Keto .07 .01 .566 uM +/- 0.31 -8.50 -4.32 +/- 0.52 -4.18 
 
 
The protein and ligand were allowed 30 minutes to equilibrate to the temperature 
before the first injection. For the first injection, only 2 μL of titrant was added, and 
another 27 injections with 10 μL each of titrant were made with 4 minute spacing 
between injections, totaling 272 μL volume added to the cell whose volume was 1.45 
mL. The protein-ligand mix in the cell was stirred at a speed of 304 rpm. The camphor 
and norcamphor titrations included the reducing agent TCEP at a concentration of 0.1 
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mM in the buffer to prevent protein degradation during the course of the experiment 
(~2.5 hrs). 
The raw data sets were processed using NITPIC [70].  Reference titrations were 
performed by injection of each ligand into the appropriate buffer to account for the heat 
of dilution in the protein-ligand titration.  The baseline was manually adjusted after the 
heat of dilution subtraction and initial automated baseline correction to ensure the best 
fit for the peak shapes. The isotherm was then saved and analyzed further in SEDPHAT 
for fitting and extraction of thermodynamic parameters.[71] The isotherms were fitted 
using the A + B → AB Hetero-Association configuration assuming a one-site binding 
model. After removing the first injection data point and other data points that were more 
than 2 standard deviations off the line likely due to air bubbles, the isotherm curve was 
best fit by a combination of Marquardt nonlinear least-squares analysis and Simplex 
fitting until both models converged. This converged fit was then used to calculate the 
binding affinity in terms of Kd and enthalpy of binding (ΔH) for each ligand-protein 
association, from which the entropy of binding was then derived (Table 5).  Final heat of 
injection, residual and isotherm plots were generated with GUSSI [72]. 
6.2 Thermodynamic parameters of CYP101-ligand complexes 
 
Binding of ligands with diverse physico-chemical properties to oxidized CYP101 
was investigated by ITC to examine the thermodynamic basis of differential ligand 
binding. Analysis of thermodynamic parameters obtained from the ITC measurements 
reveal an interesting pattern of ligand binding to CYP101 (Table 5). Camphor and 
norcamphor bind with significantly different affinities and with Kd values similar to what 
was observed in spectroscopic measurements [55]. The norcamphor binding is much 
weaker than that of camphor, which is expected since norcamphor is lacking the 
hydrogen-bond with Tyr96 side-chain that camphor is known to form and also two 
methyl groups present on camphor that might reduce the extent of hydrophobic contacts 
formed by camphor in the binding pocket of CYP101. This would explain the slightly 
exothermic nature of camphor binding versus that of norcamphor which is slightly 
endothermic in nature. However, the entropy change is more favorable for the binding 
process of both ligands and could result from solvent reorganization effects for both 
 
75 
protein and ligand. The ligand-free form of CYP101 has several bound water molecules 
lining the hydrophobic interior of the binding pocket [69]. One of the water molecules is 
ligated to the sixth coordination site on the heme and is displaced by both camphor and 
norcamphor binding as part of the high spin transition of the heme active site upon 
ligand binding. This along with possible release and/or reorganization of other water 
molecules in the binding pocket could possibly result in a more favorable entropy for the 
binding process. Since norcamphor binds weakly to CYP101 mainly due to lack of 
hydrogen-bond to Tyr96 of the protein, the flexibility of the protein is not reduced as 
much as that observed for camphor which would explain the higher average amide 
exchange rates for norcamphor-bound form relative to the camphor-bound form.  
In contrast, ketoconazole binding is a mix of enthalpy and entropy driven 
process. The docked model structure of the ketoconazole-CYP101 complex supports 
this observation. The enthalpy change upon ketoconazole binding is largely resultant 
from the interaction of the imidazole nitrogen with the heme iron. Although weak 
contacts between the polar oxygen and nitrogen atoms of ketoconazole with 
surrounding polar side-chains in CYP101 can contribute to this enthalpy change, they 
are not going to be significant based on the conformational mobility of the long chain in 
the ketoconazole structure as observed in the docked model. The weak interaction of 
the chlorinated phenyl ring with the phenyl side-chains of CYP101 in the hydrophobic 
interior again may not contribute significantly to the enthalpy change, however may 
actually contribute to the entropy change again due to the release and/or reorganization 
of water molecules in the interior of the protein. Also, ligand desolvation upon binding 
could contribute to this effect. The observation from NMR chemical shift perturbation 
and the docked structure that ketoconazole does not make any specific contacts since 
the protein is largely found in a conformation similar to the ligand-free form suggests 
that binding of large ligands such as ketoconazole does not require major change in 
CYP101 conformation to accomplish tight binding and can instead utilize minimal 
enthalpic interactions and favorable entropy from solvent reorganization for that 
purpose. Similar ITC experiments with other P450s have similarly shown that 
ketoconazole binding is a mix of enthalpy and entropy changes to varying degrees with 
entropy generally being the more dominant driving force [64].  
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Finally, the binding of nicotine is largely driven by enthalpy change due to ligation 
of nicotine imidazole nitrogen with heme iron and hydrogen-bonding interaction with 
surrounding water molecules. The nicotine ligand is a small polar molecule and thus not 
displace the water molecules significantly from the hydrophobic interior of the protein 
but instead binds to them, which would account for the unfavorable entropy of binding 
observed in the ITC experiments. 
An interesting observation made from the ITC experiments is the similar binding 
affinities for all ligands other than norcamphor, which indicates the free energy of 
binding (ΔG) remains largely unchanged for these ligands even though relative 
contribution of enthalpy and entropy vary, suggesting an enthalpy-entropy 
compensation mechanism. This mechanism is generally explained by assuming that if a 
change in the ligand causes tighter van der Waals contacts or H-bonds, it inevitably 
leads to reduced flexibility in one or both of the components reducing the overall 
conformational entropy which compensates for the enthalpy increase. Vice-versa, if the 
overall conformational entropy increases, it results in increased conformational flexibility 
with a concomitant reduction in enthalpy change. This mechanism has typically been 
invoked to explain change in conformational dynamics of the protein. In the case of 
camphor and norcamphor, an increase in overall entropy is observed which is also the 
driving force for the association of these ligands with the protein. However, amide 
exchange studies show that the conformational dynamics of the protein are actually 
reduced overall relative to the ligand-free form. Conformational entropy of the protein 
therefore is not likely the major factor in this observed increase in entropy for the 
system. Another factor that can change the entropy of the system is the water hydrating 
the system and if the ligand-protein interaction changes the amount of bound water 
either on the ligand or the protein, that could contribute to the compensatory mechanism 
[73] In case of camphor and norcamphor, they are both hydrophobic ligands with a 
predominantly non-polar character and thus their interaction with the hydrophobic 
interior of the protein can cause release of bound water changing the entropy of the 
system. The dynamics of the protein can still be altered in this case but in the opposite 
direction as release of bound water could change the dynamic landscape of the protein 
where the protein samples a more restricted conformation due to a tighter 
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rearrangement of protein-ligand contacts in the interior of the protein (e.g. nonpolar 
contacts), assuming the entropy of the ligand bound to the protein has not changed 
significantly relative to its free state. In case of camphor, the formation of hydrogen 
bond between camphor oxygen atom and Tyr96 side-chain likely adds to this restriction 
on flexibility. This hydrogen-bond is not seen in norcamphor-bound CYP101 explaining 
its slightly higher flexibility relative to camphor-bound form. 
The binding of nicotine to CYP101 also supports this explanation of role of water 
in the enthalpy-entropy compensation mechanism observed in CYP101. The crystal 
structure of nicotine bound to CYP101 apart from directly binding to the heme also 
shows direct interaction of nicotine with multiple crystallographic waters [Figure 5] that is 
not observed in the case of camphor or norcamphor. This in principle should 
considerably reduce the flexibility of nicotine-bound protein and decrease the enthalpy 
and entropy change associated with the liganded system. This is indeed what is 
observed from the ITC data, where the nicotine binding shows a large decrease in 
enthalpy of the system which is accompanied by reduced system entropy. The 
conformational dynamics of the protein in the nicotine-bound form is also reduced 
significantly and is the least among all the ligands examined here.  
The binding of ketoconazole is intermediate in terms of compensatory 
mechanism between that of camphor/norcamphor and nicotine. The enthalpy and 
entropy change are equally favorable as observed from the ITC data and with NMR 
spectra showing little to no change in the conformational flexibility of CYP101 upon 
ketoconazole binding. As discussed earlier, while a large ligand such as ketoconazole is 
potentially capable of forming several intermolecular contacts with the protein, the 
docked structure and minimal NMR chemical shift perturbations in this case suggest 
otherwise. Therefore, the binding of ketoconazole is not enthalpy dominated but is a mix 
of both favorable enthalpy and entropy change, with the main enthalpic contribution 
coming from the direct interaction of ketoconazole with the heme. This interaction 
should not perturb the protein structure much and therefore the flexibility of 
ketoconazole-bound CYP101 is not affected significantly but is similar to that of the 
ligand-free form. Such differential enthalpy-entropy compensation has also been seen 
previously in other P450s such as CYP2B4 when studied with a series of inhibitors of 
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varying chemical characteristics, where CYP2B4 changes conformation and becomes 
more compact in the presence of some inhibitors, but not with all [74]. 
An important aspect that is not included in the above discussion is the fact that 
the dynamic changes in the protein when binding to camphor, norcamphor and nicotine 
ligands are manifested over the entire protein. Especially, in the case of nicotine-bound 
form, the dynamic changes are quite dramatic and lead to almost complete loss of 
flexibility throughout the protein. Such an observation can be explained by utilizing the 
concept of enthalpy-entropy transduction in which local thermodynamic forces such as 
ligand binding enthalpies can be transduced into different global thermodynamics via 
conformational selection [75] In this mechanism, proteins that can bind a series of 
ligands are prone to sample different conformations of similar free energy but different 
enthalpy and entropy. As a consequence, the same protein can bind different ligands 
with similar free energies but with different entropies and enthalpies. In this way, this 
transduction mechanism can lead to a highly linear enthalpy-entropy compensation 
mechanism, which is what is likely observed in our case. It should be noted that this 
transduction mechanism does not preclude the role of water in this compensation 
mechanism. An added characteristic that results from this transduction is selective 
stabilization of certain conformational states that can lead to complete transformation of 
protein dynamics at a global level. Our observations support such a transduction 
mechanism in CYP101 based on dramatic global dynamic changes and conformational 
selection observed by NMR for nearly all ligands studied so far. This has experimentally 
not been demonstrated for any protein previously to the best of our knowledge, although 
the concept and relevant theory from analysis of simulations has been around for a few 
years[75]. More studies are needed to confirm and characterize this phenomenon in 
CYP101 and other P450s. If validated, this will open up a new paradigm in the area of 































CHAPTER SEVEN:  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 Summary of Project and Conclusions 
 
Understanding of protein dynamics in context of protein function is an important 
biological goaI. The cytochrome P450 system offers a valuable paradigm to understand 
protein dynamics in context of differential ligand binding where a vast multitude of 
P450s are able to recognize millions of diverse ligands. In this research project, an 
investigation of the dynamic changes that happen in a model P450 system, CYP101, 
upon binding a suite of different ligands was undertaken in an effort to address this 
aspect. Solution NMR spectroscopy was chosen as the method of choice since it is able 
to characterize the dynamic processes on a variety of timescales. NMR data from amide 
exchange measurements helped elucidate the slow timescale motions of CYP101 in 
complex with various ligands and comparison with the dynamics of ligand-free form 
allowed us to map the dynamic differences resulting from ligand binding. An important 
finding from this comparison was that the dynamic differences are not just restricted to 
the flexible SRS regions but are observed throughout the protein. This validates the 
preliminary observations from 2D NMR HSQC spectra where considerable effects were 
seen in terms of line-broadening, peak intensities and peak splittings throughout the 
NMR spectra indicating that the protein responds to the ligand event as a whole. This 
finding also strengthens results from previous neutron scattering studies on the same 
system which demonstrated that collective motions on ps-ns timescales span across the 
protein and facilitate opening and closing of the ligand access channel. Thus, the role of 
dynamics in the protein is clearly linked to its function. 
The project required overcoming multiple challenges, both in terms of 
methodology and also in interpretation of diverse sets of data. A large number of 
isotopically labeled samples, both uniform and selective labeled, were made and used 
within multidimensional NMR experiments to collect and assign resonances in CYP101 
as a first step before acquisition of dynamic data. This included several 3D NMR 
experiments on five different CYP101 forms, 2D NMR experiments on multiple 
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selectively labeled samples again on five different CYP101 forms, followed by collection 
of several sets of amide exchange data on all of these forms. All of these experiments 
resulted in a total close to 200 individual spectra that were collected, processed and 
analyzed over the course of this project. This not only allowed augmenting of the 
existing backbone and sidechain resonance assignments available for CYP101 in 
ligand-free and camphor-bound forms, but also helped provide additional assignments 
for the three other forms of CYP101 not previously available. These assignments 
provided substantial coverage in monitoring important regions of the protein such as the 
SRS as well as other regions outside of the protein that are dynamic and were critical in 
obtaining dynamic insights on these regions from the amide exchange studies. In 
addition to the NMR experiments, molecular docking methods were employed to obtain 
a reasonable structural model for the CYP101-ketoconazole complex which was then 
used in the interpretation of the dynamic data for this complex.  
Finally, ITC experiments were also performed to gain insights into the 
thermodynamic basis of ligand binding to CYP101 for all 4 ligands examined in this 
project. The dissection of thermodynamic parameters for each ligand binding to 
CYP101 clarified the thermodynamic driving force for each binding event and revealed 
interesting patterns in terms of enthalpy-entropy compensation mechanisms for this 
series of ligands. A valuable aspect of this study was the insight that water associated 
with the protein may be involved in this compensation mechanism, something which is 
overlooked frequently in structural studies of ligand binding in the P450 area. Based on 
the ITC data and its correlation with the observed protein dynamics from NMR 
experiments, a novel enthalpy-entropy transduction mechanism was suggested to 
explain the differential change in dynamics upon ligand binding, which creates a 
fascinating link between dynamic and thermodynamic characteristics of the protein. This 
framework provides an integrated view of protein dynamics and thermodynamics and 
would be very useful in practical aspects of manipulating ligand binding to flexible 





7.2 Future Directions 
 
Only slow timescale motions for CYP101 from amide exchange measurements 
were characterized in this project. However, as the 2D NMR spectra of CYP101 with 
different ligands clearly show that the dynamics of CYP101 is occurring on multiple 
timescales depending on the ligand bound. Therefore, a logical next step in the future 
would be to do a dynamic characterization with the same ligand-bound forms on other 
timescales, such as fast and intermediate, using NMR spectroscopy. The availability of 
an expanded set of resonance assignments from the current project should benefit this 
characterization and speed up the process of dynamic analysis of data from these new 
experiments. Such a complete characterization of dynamic differences on multiple 
timescales in this system will go a long way in garnering additional insights into the 
dynamic mode of differential ligand binding and help test whether enthalpy-entropy 
transduction mechanism is operating on these timescales as well.  ITC experiments 
could also be conducted in the presence of various osmolytes to confirm the role of the 
water network in ligand binding[76]. An efficient way to assess the enthalpy-entropy 
transduction mechanism would be to perform titration experiments on CYP101 with the 
different ligands to monitor dynamic changes as a function of ligand concentration. This 
would provide evidence for whether individual ligands go through a different 
conformational selection pathway to accomplish this transduction. This can easily be 
followed by observing chemical shifts as they transition through different populated 
states starting from the ligand-free state to reach the final conformation most compatible 
with a certain ligand. Such experiments are currently in progress and preliminary results 
(data not shown) show strong evidence for such a mechanism in a ligand-dependent 
manner. When completed, these experiments will help make important progress 
towards a long-sought goal of linking the conformational dynamics with thermodynamics 



























Table A.1 NMR Chemical shift Assignments for oxidized Cyp101 in complex with 
the substrates camphor and norcamphor 
















LEU 11 N term Loop 7.63 122.24 53.8 7.6 122.14 53.9 
ALA 12 N term Loop 8.617 130.2 51.3 8.64 130.1  
HIS 17 N term Loop 7.71 112.2 56.7 7.72 112.1 56.6 
VAL 18 N term Loop 6.8 127.8 60.9 6.82 127.5  
LEU 22 N term Loop 6.88 119.3 54.5    
VAL 23 N term Loop 7.1 121.1 63.78 7.11 120.89 63.6 
PHE 24 N term Loop 9.15 133.7 58.7 9.23 133.75  
PHE 26 N term Loop 8.3 125.25 58.5 8.32 125.2 61.6 
ASP 27 N term Loop 8.34 133.14  8.14 133.4  
TYR 29 N term Loop 7.89 118.8 60.3 7.95 119.5 60.1 
ASN 30 N term Loop 6.74 116.84 52.4 6.83 116.64  
ALA 36 N term Loop 7.809 124.96 53.6 7.81 125 53.4 
GLY 37 A Helix 7.41 109.9 43.2 7.4 109.8  
ASN 49 Aβ1 Loop 8.267 116.9 54.12 8.27 116.8 53.6 
VAL 50 Aβ1 Loop 7.749 126.3 61.35 7.72 125  
VAL 54 β1 Sheet 8.56 113.8 58.79 8.5 113.72 58.7 
TRP 55 β1 Sheet 8.92 123.54 56.1 8.96 123.44 56.3 
THR 56 β1 Sheet 7.9 120.4 58.6 7.9 120.38  
CYS 58 β1 Sheet 8 119.56 59.55 7.99 119.46 59.3 
ASN 59 β1 Sheet 9.22 115.3 56.3 9.29 115.6 56.2 
GLY 60 β1 Sheet 8.7 104.3 45.675 8.83 104.4 45.8 
GLY 61 β1 Sheet 7.45 112.2 45.068 7.5 112.4 44.8 
HIS 62 β1 Sheet 7.11 122.07 56.25 7.14 122  
TRP 63 β1 Sheet   57.0118    
ILE 64 β1 Sheet 10.4 126.2 63.011 10.37 126.2 62.8 
ALA 65 β1 Sheet 7.89 128.9 51.7 7.8 128.9 51.1 
THR 66 β1 Sheet 8.6 109.46 62.8 8.56 109.337 62.8 
ARG 67 B Helix 6.49 115.14 52.98 6.38 115.1  
GLY 68 B Helix 10.48 112.7 47 10.3 112.57 47.8 
GLN 69 B Helix 8.91 120.1 59.7 8.89 120.3 59.7 
LEU 70 B Helix 6.43 117.4 59.7 6.32 117.46  
CYS 85 BB' Loop 5.74 111.7 54.75 5.78 111.87  





Table A.1 continued 
ILE 88 BB' Loop 5.78 121.88 58.02    
ARG 90 B' Helix 9.38 124.77 61.06 9.37 125.4 61.3 
GLU 91 B' Helix 9.378 116.53 60.56 9.39 117  
ALA 92 B' Helix 7.2 123.7 54.776 7.23 123.2  
GLY 93 B' Helix 7.3881 104.83 48.082 7.52 104.84  
GLU 94 B' Helix 8.94 121.97 59.62 8.94 121.73  
ALA 95 B' Helix 6.88 120.48 53.4 6.9 119.9 52.5 
TYR 96 B' Helix 7.3282 121.91 60.37 7.25 121.6  
PHE 98 B'C Loop 5.78 121.88 57.9    
PRO 122 C Helix   66.3   66.3 
VAL 123 C Helix 7.22 116.6 65.48 7.14 117.2 65.33 
VAL 124 C Helix 7.46 122 67.4 7.45 121.9 67.4 
ASP 125 C Helix 8.2 118.6 58.1 8.2 118.9 58 
LYS 126 C Helix 7.26 119 58.9 7.19 119.26  
SER 141 D Helix 7.62 113.3 57 7.62 113.3  
GLN 145 D Helix 8.33 114.445 58.2 8.35 114.24 57.5 
GLY 146 DE Loop 6.5 102.27 44.81 6.54 102.14  
GLN 147 DE Loop 5.93 111.72 54.7 5.97 111.64 54.4 
CYS 148 DE Loop 8.28 111.05 57.36 8.29 110.98 57.1 
ASN 149 E Helix 9.18 120.3 52.7 9.18 120.2  
PHE 150 E Helix 9.32 124.8 63.8 9.32 124.8 63.8 
THR 151 E Helix 7.25 109.5 65.1 7.59 111.5  
GLU 152 E Helix 6.27 118.9 58.31   58.3 
ASP 153 E Helix 8.6 115.1 56.2 8.68 115.1  
MET 164 E Helix   58.3    
LEU 165 E Helix 7.7 121.19 58.66    
LEU 166 E Helix 8.2 123.6 58.7   58.5 
ALA 167 E Helix 8.67 119.2 53.65 8.68 119.47  
GLY 168 E Helix 7.92 109.44 47.521 7.8 110.58  
GLU 171 EF Loop 8.75 123.1 60.1 8.66 123.43 59.9 
GLU 172 EF Loop 9.42 120.37 59.7 9.4 120.24  
LYS 178 F Helix 8.1 119.03 59.8 8.14 119.58 59.3 
TYR 179 F Helix 7.14 118.7 61.8 7.59 119  
THR 185 F Helix 7.63 107.32 59.5 7.24 107.2  
ASP 188 FG Loop 8.37 127.1 53.9 8.34 127 53.5 
GLY 189 FG Loop 8.5 110.66 45.5 8.45 110.09 45.3 
SER 190 FG Loop 8.61 120 61.3 8.7 120 61 
MET 191 FG Loop 8.16 120.7 55.9 8.17 120.829 55.5 
THR 192 G Helix 8.7 117 62.1 8.66 116.9  





Table A.1 continued 
ALA 194 G Helix 8.39 119.4 56.08 8.455 119.61  
GLU 198 G Helix 7.72 117.2 58.2 7.66 117.24 58 
ALA 199 G Helix 7.373 121.68 55.13 7.23 121.7 55.1 
LEU 200 G Helix 7.85 124.4 58.3 7.88 125.3  
PRO 206 G Helix   65.7    
ILE 207 G Helix 6.6 119.3 55.8 6.65 119.37 55.5 
ILE 208 G Helix 8.27 121.4 63.8 8.28 121.66  
LYS 214 G Helix 8.34 116.6 60.4 8.4 116.67  
PRO 215 GH Loop   64.29   63 
GLY 216 GH Loop 8.52 111.517 43.9 8.53 111.4  
THR 217 GH Loop 8.092 117.97? 62    
ALA 219 H Helix 8.55 118.8     
ILE 220 H Helix 7.89 115.2 65.4 7.8 114.3  
VAL 223 H Helix 7.85 119.06 67.4 7.79 119 67.2 
ALA 224 H Helix 9.04 117.1 55 9 117.07 54.5 
ASN 225 H Helix 7.2 113 53.4 7.24 113.2 53.4 
GLY 226 β2 Sheet 7.72 110.2 45.65 7.7 109.9 46.2 
GLN 227 β2 Sheet 8.092 118.58 55.1 7.99 118.9 55.01 
VAL 228 β2 Sheet 8.922 118.17 60.42 8.92 118.14  
ASN 229 β2 Sheet 8.9 121.9 no ca?   54.3 
GLY 230 β2 Sheet 8.55 103.7 45.1 8.6 103.66 46.1 
ARG 231 β2 Sheet 7.98 119.5 53.23 7.97 119.5  
ILE 233 β2 Sheet 8.237 127.2 62.4 8.24 127.15 62.4 
THR 234 I Helix 9.09 120.1 61.38 9.04 119.9  
ALA 265 I Helix 8.21 121.2 54.86 8.21 121.2  
LYS 266 I Helix 7.13 116.49 57.7 7.27 116.38  
SER 267 I Helix 7.09 115.53 63.7 7.02 115.86  
HIS 270 J Helix      59.3 
ARG 271 J Helix 7.6 117.9 61.5 7.62 117.87 61.4 
GLN 272 J Helix 8.35 117.4 59.2 8.39 117.2 59 
GLU 273 J Helix 7.47 119.23 60.4 7.5 119.7 60.3 
LEU 274 J Helix 7.03 115.8 56.6 7.07 115.69  
GLU 279 JK Loop 9.98 122.35 58.8 10.04 122.37 58.6 
ARG 280 K Helix 8.53 121.2 57 8.59 121.24  
ASP 304 β3β4 Loop 8.46 121.79 55.7 8.46 121.7 55.3 
TYR 305 β4 Sheet 8.43 126.6 55.6 8.43 126.63 55.3 
GLU 306 β4 Sheet 7.69 130.54 57.28 7.66 130.3  
PHE 307 β4 Sheet 8.4933 130.335 55.3 8.49 130.3 54.9 
HIS 308 β4 Sheet 8.92 124.2 57.9 8.937 123.95 57.4 





Table A.1 continued 
VAL 310 β4 Sheet 7.537 124.17 61.93 7.51 124.1 61.49 
GLN 311 β4 Sheet 8.37 126.35 56.83 8.38 126.2 56.6 
LEU 312 β4 Sheet 8.65 128.9 54.32 8.65 128.75 54 
LYS 313 β3β4 Loop 8.5706 124.97 54.36 8.46 124.7 53.9 
LYS 314 β3β4 Loop 8.74 122.4 59.2 8.7 122.25 59 
GLY 315 β3 Sheet 8.63 117.64 46.1 8.61 117.67 45.6 
ASP 316 β3 Sheet 8.96 123.19 56.2 8.94 123.33 55.9 
GLN 317 β3 Sheet 9.47 119.2 56.4 9.45 119.14  
ILE 318 β3 Sheet   58.8    
LEU 319 β3 Sheet 9.13 131.5 55.4 9.07 131.1  
LEU 320 β3 Sheet 8.83 132.2 52 8.77 131.6  
ALA 333 β3L loop 8.464 124.6 53 8.54 125.1  
MET 336 β3L loop 8.724 116.86 58.3 8.71 116.87  
HIS 337 β3L loop 8.21 123.8 56.3 8.06 123.6  
VAL 338 β3L loop 8.04 127.1 62.2 8.06 126.89  
ASP 339 β3L loop 10.15 131.6 52.58 10.1 131.87 52.1 
PHE 340 β3L loop 9.496 124.71 52.48 9.49 124.9 52.7 
SER 341 β3L loop 8.72 116.51 58.42 8.59 116.01 58.2 
ARG 342 β3L loop 7.18 124.5 57.01 7.23 124.51  
ILE 368 L Helix   58    
VAL 369 L Helix 7.52 109.2 60 7.42 109.8  
LYS 372 L Helix 8.8 120.8 55.7 7.26 119  
PRO 379 Lβ5 Loop   64.78    
ASP 380 Lβ5 Loop 8.134 116.8 54.06 8.15 117 53.6 
PHE 381 Lβ5 Loop 6.634 119.9 56.019 6.64 119.34 55.5 
SER 382 β5 Sheet 9.04 111.8 57.8 9.08 111.79 57.3 
ILE 383 β5 Sheet 8.51 123.01 61.3 8.51 123 61.1 
ALA 384 β5 Sheet 8.157 132.1 52 8.17 132.12  
GLY 386 β5 Sheet 8.5 111.5 44.3 8.48 111.35 45.8 
ALA 387 β5 Sheet 7.61 124.1 53.3 7.62 124.2 53.04 
GLN 388 β5 Sheet 8.41 123 54.8 8.38 122.93 54.7 
ILE 389 β5 Sheet 8.56 127.1 59.8 8.54 127.3 59.5 
GLN 390 β5 Sheet 9.48 129.9 54.9 9.47 129.6 54.9 
HIS 391 β5 Sheet 8.97 125.8 53.7 8.89 125.9 53.4 
LYS 392 β5 Sheet 8.89 119.2 56 8.87 119.5 55.5 
SER 393 β5 Sheet 8.73 117.68 56.1 8.84 117.86 56 
GLY 394 β5 Sheet 6.78 110.4 46.5 7.02 111.42  
VAL 396 β5 Sheet 5.91 114.7 61.2    






Table A.1 continued 
GLY 398 β5 Sheet 8.54 103.11 46.113 8.61 103.2  
VAL 399 β5 Sheet 8.06 119.8 63.04    
GLN 400 β5 Sheet 8.93 126.3 53.8 8.95 126.4  
ALA 401 β5 Sheet 7.355 117.5 52.6 7.37 118.2 52.6 
LEU 402 β5 Sheet 8.63 120.1 55.9 8.76 119.87  
VAL 405 β5 Sheet 9.22 114.49 60.1 9.2 114.67  
ALA 409 C term Loop 8.68 121.79 55.1 8.7 122  
THR 410 C term Loop 8.15 108.76 62.2 8.15 108.66  
LYS 412 C term Loop 8.9257 121.35 55.9 8.98 121.1  
ALA 413 C term Loop 8.073 125.4 52.27 8.05 125.8  
VAL 414 C term Loop 7.9 127.1 64.8 7.91 126.94  




















Table A.2  A1 NMR Chemical shift Assignments for oxidized Cyp101 in ligand-free 
form 






Ligand Free  
N(ppm) 
Ligand Free  
Cα(ppm) 
LEU 11 N term Loop 7.8 122.6 54.1 
ALA 12 N term Loop 8.6 130.16 50.7 
PRO 16 N term Loop   64.12 
HIS 17 N term Loop 7.66 112 56.3 
VAL 18 N term Loop 6.77 127.5 60 
LEU 22 N term Loop 7.05 119.2 54.4 
VAL 23 N term Loop 7.064 120.7 62.9 
PHE 24 N term Loop 9.2 133.83 58 
PHE 26 N term Loop 8.33 126 58.5 
ASP 27 N term Loop 8.234 133.14 50.1 
TYR 29 N term Loop 7.97 118.06 59.2 
ASN 30 N term Loop 6.81 116.21 52.06 
ALA 36 N term Loop 7.74 124.8 52.8 
GLY 37 A Helix 7.36 109.8 44 
ASN 49 Aβ1 Loop 8.23 116.73 53.6 
VAL 50 Aβ1 Loop 7.67 126.2 60.77 
VAL 54 β1 Sheet 8.54 113.7 58.2 
TRP 55 β1 Sheet 8.88 123.1 55.6 
THR 56 β1 Sheet 7.82 122.6 58.9 
CYS 58 β1 Sheet 8 119.4 58.97 
ASN 59 β1 Sheet 9.28 115.6 55.7 
GLY 60 β1 Sheet 8.76 104.1 44.72 
GLY 61 β1 Sheet 7.46 112.2 43.8 
HIS 62 β1 Sheet 7.12 122 55.74 
ILE 64 β1 Sheet 10.3 125.9 62.39 
ALA 65 β1 Sheet 7.7 128.77 50.93 
THR 66 β1 Sheet 8.44 109.58 61.99 
ARG 67 B Helix 6.2 114.65 52 
GLY 68 B Helix 10.15 112.18 46.98 
GLN 69 B Helix 8.71 120.1 58.9 
LEU 70 B Helix 6.21 116.8 58.8 
CYS 85 BB' Loop 5.77 117.84 55.7 
ARG 90 B' Helix 9.29 126 62.7 
GLU 91 B' Helix 9.2 113.47 59.3 





Table A.2 Continued 
GLY 93 B' Helix 7.68 104.32 45.94 
GLU 94 B' Helix 8.92 121.55  
ALA 95 B' Helix 7.15 119.56 53.8 
TYR 96 B' Helix 7.43 120.9 59.6 
VAL 123 C Helix 7.12 118.6 67.9 
VAL 124 C Helix 7.44 121.8 66.8 
LYS 126 C Helix 7.15 119.6 58.9 
SER 141 D Helix 7.52 113.1 56.5 
GLN 145 D Helix 8.24 113.83 57.74 
GLY 146 DE Loop 6.5 102.04 44.4 
GLN 147 DE Loop 5.86 110.71 54.1 
CYS 148 DE Loop 8.22 110.74 56.7 
ASN 149 E Helix 9 119.4 52.7 
PHE 150 E Helix 9.32 124.8 62.7 
THR 151 E Helix 7.07 109.14 65.1 
GLU 152 E Helix 6.54 118.9 57.3 
ASP 153 E Helix 8.68 115.3 56.07 
LEU 165 E Helix 7.8 120.2 58.8 
ALA 167 E Helix 8.74 120.2 52.5 
GLY 168 E Helix 7.38 109.37 47.6 
GLU 171 EF Loop 8.65 123.09 59.5 
GLU 172 EF Loop 9.29 119.82 59 
LYS 178 F Helix 8.03 119.5 58.9 
THR 185 F Helix 6.72 107.96  
ASP 188 FG Loop 8.4 126.4 53.1 
GLY 189 FG Loop 8.44 109.9 45 
SER 190 FG Loop 8.54 119.7 59.77 
MET 191 FG Loop 8.16 121.19 56.33 
THR 192 G Helix 8.56 116.48 62.3 
ALA 194 G Helix 8.37 119.8 55.3 
ALA 196 G Helix 7.84 126.27 55.9 
LYS 197 G Helix 8.15 118.1 54.3 
GLU 198 G Helix 7.75 117.12 57.6 
ALA 199 G Helix 7.11 122 55.6 
LEU 200 G Helix 8.02 124.7 57.9 
ILE 207 G Helix 6.61 118.96 63.9 
ILE 208 G Helix 8.2 122.2 61.9 
LYS 214 G Helix 8.4 117.15 58.4 






Table A.2 continued 
ILE 220 H Helix 7.67 113.9  
VAL 223 H Helix 7.55 118.98 66.3 
ALA 224 H Helix 8.9 117.2 54.5 
GLY 226 β2 Sheet 7.63 109.58 45.1 
GLN 227 β2 Sheet 8.14 118.8 54.6 
VAL 228 β2 Sheet 8.76 117.63 59.9 
GLY 230 β2 Sheet 8.56 103.4 45.6 
ARG 231 β2 Sheet 7.88 119 52.64 
ILE 233 β2 Sheet 8.28 127.4 61.99 
THR 234 I Helix 8.97 119.98 60.7 
ALA 265 I Helix 8.23 121.67 55.3 
LYS 266 I Helix 7.32 116.47 57.1 
SER 267 I Helix 6.98 115.9 62.6 
GLU 273 J Helix 7.46 119.1 59.7 
LEU 274 J Helix 7.02 115.65 55.9 
GLU 279 JK Loop 10.02 122 58.1 
ARG 280 K Helix 8.56 121.2 56.5 
ASP 304 β3β4 Loop 8.44 121.56 55 
TYR 305 β4 Sheet 8.34 126.7 55 
GLU 306 β4 Sheet 7.65 130.2 56.44 
PHE 307 β4 Sheet 8.43 130 54.5 
HIS 308 β4 Sheet 8.9 123.9 57.1 
GLY 309 β4 Sheet 8.3 102.7 45 
VAL 310 β4 Sheet 7.45 124 61.6 
GLN 311 β4 Sheet 8.33 126.35 56.22 
LEU 312 β4 Sheet 8.57 128.7 53.7 
LYS 313 β3β4 Loop 8.49 124.51 53.6 
LYS 314 β3β4 Loop 8.69 121.2 58.8 
GLY 315 β3 Sheet 8.56 117.5 44.1 
ASP 316 β3 Sheet 8.8 123.12 55.6 
GLN 317 β3 Sheet 9.35 118.9 55.5 
LEU 319 β3 Sheet 9.04 130.8 54.7 
LEU 320 β3 Sheet 8.6 131.6 50.8 
ALA 333 β3L loop 8.46 124.5 52.3 
MET 336 β3L loop 8.7 116.8 57.8 
HIS 337 β3L loop 8 124.5 55.9 
VAL 338 β3L loop 8.01 126.9 61.5 
ASP 339 β3L loop 10.07 131.4 51.87 
PHE 340 β3L loop 9.28 125.9 51.8 





Table A.2 continued 
ARG 342 β3L loop 7.22 124.53 56.3 
VAL 369 L Helix 7.3 110.6 60 
LYS 372 L Helix 8.93 121.29 55.2 
ASP 380 Lβ5 Loop 8.1 116.77 53.5 
PHE 381 Lβ5 Loop 6.57 119.23 55.26 
SER 382 β5 Sheet 9.08 111.67 57 
ILE 383 β5 Sheet 8.5 122.67 60.39 
ALA 384 β5 Sheet 8.1 131.8 51.4 
GLY 386 β5 Sheet 7.64 109.5 45.1 
ALA 387 β5 Sheet 7.64 123.9 52.7 
ILE 389 β5 Sheet 8.599 126.8 58.99 
GLN 390 β5 Sheet 9.51 129.8 54.6 
HIS 391 β5 Sheet 8.89 125.4 54.42 
LYS 392 β5 Sheet 8.77 119.07 54.2 
SER 393 β5 Sheet 8.86 117.9 55.4 
GLY 394 β5 Sheet 6.92 110.92  
GLY 398 β5 Sheet 8.57 103.44 45.73 
GLN 400 β5 Sheet 8.99 126.34 53.2 
LEU 402 β5 Sheet 8.73 121 54.7 
VAL 405 β5 Sheet 9.19 114.23 59.6 
ALA 409 C term Loop 8.84 122.72 55.5 
THR 410 C term Loop 8.1 108.21 61.8 
LYS 412 C term Loop 8.95 121.22 55.3 
ALA 413 C term Loop 8.04 125.6 51.7 
VAL 414 C term Loop 7.87 126.88 63.9 

















Table A.3 A1 NMR Chemical shift Assignments for oxidized Cyp101 in complex 
with nicotine and ketoconazole (keto)  
















LEU 11 N term Loop 7.64 122.1 54.2 7.68 122.6 54.01 
ALA 12 N term Loop 8.67 130.3 51.4 8.6 130.01 51.1 
PRO 16 N term Loop     64.9   65.1 
HIS 17 N term Loop 7.66 111.9 56.9 7.67 111.97 56.89 
VAL 18 N term Loop 6.7 127.4 60.9 6.77 127.45 60.8 
LEU 22 N term Loop 6.89 120 53.9 6.86 119.85 54.3 
VAL 23 N term Loop 7.04 120.89 63.62 7.04 120.75 63.7 
PHE 24 N term Loop 9.2 133.8 58.9 9.14 133.8 58.7 
PHE 26 N term Loop 8.27 124.8 58 8.28 125.2  
ASP 27 N term Loop       8.188 132.28  
TYR 29 N term Loop 8 119 60.19 8 118 60.3 
ASN 30 N term Loop 6.8 116.9 52.18 6.85 116.68 52.6 
ALA 36 N term Loop 7.75 124.8 53.57 7.74 124.9 53.5 
GLY 37 A Helix 7.37 109.7 43.4 7.31 109.7 44.2 
ASN 49 Aβ1 Loop 8.1 115.5 54 8.24 116.92 54.1 
VAL 50 Aβ1 Loop 7.72 126.2 61.41 7.6 125.93 61.5 
VAL 54 β1 Sheet 8.47 113.8 58.36 8.49 113.72 58.9 
TRP 55 β1 Sheet 8.82 122.1 55.8 8.87 123.4 56.3 
THR 56 β1 Sheet 7.9 120.4 59.6 7.88 120.3 58.6 
CYS 58 β1 Sheet 7.77 119.58 59.3 8.01 119.54  
ASN 59 β1 Sheet 9.29 115.47 55.98 9.29 115.81 56.4 
GLY 60 β1 Sheet 8.83 104.5 45.1 8.78 104.3 45.9 
GLY 61 β1 Sheet 7.49 112.24 44.44 7.51 112.19 44.9 
HIS 62 β1 Sheet 7 121.85 56.3 7.11 122.49 56.41 
ILE 64 β1 Sheet 10.34 126 62.5 10.26 125.88 63.1 
ALA 65 β1 Sheet 7.67 129 51 7.75 128.7 51.3 
THR 66 β1 Sheet 8.41 109.39 62.6 8.42 109.08 62.7 
ARG 67 B Helix 6.248 115 52.2 6.24 114.65 52.51 
GLY 68 B Helix 10.17 112.2 45 10.2 112.61 47.8 
GLN 69 B Helix 8.58 120.2 59.75 8.74 119.88 59.6 
LEU 70 B Helix 6.22 117.56 59.7 6.21 117.56 59.7 
CYS 85 BB' Loop 5.66 111.97 55.1 5.76 112.17 55.3 
PRO 86 BB' Loop     64.7    
PHE 87 BB' Loop 6.05 117.24 54.6    






Table A.3 continued 
ALA 92 B' Helix 7.33 123.77 54.38    
GLY 93 B' Helix 7.54 105 49.9 7.76 104.665 45.9 
GLU 94 B' Helix 9.01 121.82 59.2 8.89 121.7 59.1 
ALA 95 B' Helix 7.09 120.4 53 6.85 121.5 54.2 
TYR 96 B' Helix 7.2 120.51 60.2 7.25 119.65 60.2 
PHE 98 B'C Loop 6.05 121.8 57.7    
VAL 123 C Helix 7.22 116.5 65.1 7.2 118.3 65.48 
VAL 124 C Helix 7.42 122 67.4 7.48 121.4 67.4 
ASP 125 C Helix 8.2 118.6 58.1 8.1 118.7 58.1 
LYS 126 C Helix 7.09 120 58.9 7.19 119.45 59 
SER 141 D Helix 7.58 113.5 56.6 7.65 113.3 57 
GLN 145 D Helix 8.28 114.3 58.27 8.25 114 58.4 
GLY 146 DE Loop 6.5 102.18 44.8 6.47 102.44 44.4 
GLN 147 DE Loop 5.88 111.55 54.7 5.93 111.7  
CYS 148 DE Loop 8.24 110.95 57.54 8.24 111.04 57.48 
ASN 149 E Helix 9.17 120.1 52.7 9.1 119.9 52.7 
PHE 150 E Helix 9.32 124.9 63.8 9.4 124.6 63.8 
THR 151 E Helix 7.25 109.5 65.1 7.05 109.2 65.9 
GLU 152 E Helix 6.27 118.9 58.31    
ASP 153 E Helix 8.6 115.1 56.2 8.67 115.2 56.4 
LEU 165 E Helix       7.73 120.9 57.38 
LEU 166 E Helix 8.46 123.1 60.9 8.05 124.16 58.5 
ALA 167 E Helix 8.76 120.05 53 8.67 119.17 53.4 
GLY 168 E Helix 7.57 109.37 47.2 7.38 109.61 44 
GLU 171 EF Loop 8.66 123.5 59.8 8.67 123.65 60.23 
GLU 172 EF Loop 9.35 120.38 59.8 9.3 119.34 59.9 
LYS 178 F Helix 8.11 119.55 59.5 7.9965 119.5 59.7 
TYR 179 F Helix 7.12 119.55   7.59 119  
THR 185 F Helix 7.16 106.8   7.17 107.4  
ASP 188 FG Loop 8.39 127.2 53.3 8.36 126.79 53.6 
GLY 189 FG Loop 8.72 110.8 45.33 8.57 110.3 47 
SER 190 FG Loop 8.66 119.9 61.3 8.62 119.7 60.7 
MET 191 FG Loop 7.87 120.9 55.9 8.27 121.6 56.1 
THR 192 G Helix 8.9 117 61.3 8.57 116.24 61.93 
PHE 193 G Helix 8.59 123.5 61.6    
ALA 194 G Helix 8.38 118.21 55.6 8.36 119.6 56.1 
ALA 196 G Helix 7.67 125.5 55.9 7.4 125.2 55.97 
LYS 197 G Helix 8.23 118.5 55.3 8.11 118.2 55.2 
GLU 198 G Helix 7.84 117.2 59.4 7.77 117.12 58.2 





Table A.3 continued 
LEU 200 G Helix 7.97 124.1 58.7 8.02 124.33 58.6 
ILE 207 G Helix 6.62 119.8 56 6.6 119.17 55.97 
ILE 208 G Helix 8.21 121.46 60.93 8.18 122.16 63.3 
LYS 214 G Helix 8.37 116.72 59.3 8.17 116.6 60.1 
GLY 216 GH Loop 8.49 111.3 43.6 8.49 111.3 44.6 
ALA 219 H Helix 8.44 118.42 53.2    
ILE 220 H Helix 7.53 114.8 65.4 7.6 114.3 63.8 
VAL 223 H Helix 7.5 119.1 67.4 7.58 118.3 67.5 
ALA 224 H Helix 8.88 116.87 55 8.92 117.4 54.9 
GLY 226 β2 Sheet 7.62 110 46.2 7.67 109.63 46.2 
GLN 227 β2 Sheet 7.99 118.2 55 8.1 118.26 55.1 
VAL 228 β2 Sheet 8.857 118.17 60.3 8.7 118.2 60.48 
ASN 229 β2 Sheet 8.94 121.7      
GLY 230 β2 Sheet 8.63 103.53 45.1 8.57 103 46.6 
ARG 231 β2 Sheet 7.85 119.39 53.2 7.91 119.37 52.91 
ILE 233 β2 Sheet 8.167 127.13 62.43 8.21 127.45 62.6 
THR 234 I Helix 8.977 119.85 61.47 9.035 119.66 61.53 
ALA 265 I Helix 8.16 121.9 55.9 8.256 121.2 54.87 
LYS 266 I Helix 7.16 116.6 56.2 7.2 116.47 57.65 
SER 267 I Helix 7.014 116.49 62.9 7.05 116 63.4 
HIS 270 J Helix         59.62 
ARG 271 J Helix       7.59 118.17 61.6 
GLN 272 J Helix       8.35 117.1 59.2 
GLU 273 J Helix 7.53 119.4 59.9 7.48 119 60.5 
LEU 274 J Helix 7.03 115.8 56.2 7.04 115.98 56.7 
GLU 279 JK Loop 10.05 122.67 58.4 10.01 122.35 58.8 
ARG 280 K Helix 8.55 121.1 57.2 8.54 121.18 57 
ASP 304 β3β4 Loop 8.4 121.94 55.7 8.43 121.94 55.7 
TYR 305 β4 Sheet 8.4 126.6 55.7 8.45 126.7 55.4 
GLU 306 β4 Sheet 7.52 130.49 56.7 7.58 130.44 57.3 
PHE 307 β4 Sheet 8.46 130.4 54.5 8.44 130.07 55.2 
HIS 308 β4 Sheet 8.8 124.4 57.8 8.85 124 57.8 
GLY 309 β4 Sheet 8.23 102.74 45 8.25 102.67 45 
VAL 310 β4 Sheet 7.48 124 61.96 7.4 124 61.93 
GLN 311 β4 Sheet 8.29 126.3 57.13 8.34 126.3 56.78 
LEU 312 β4 Sheet 8.57 128.75 54.2 8.57 128.7 54.2 
LYS 313 β3β4 Loop 8.47 124.62 54.3 8.47 125.1 54.4 
LYS 314 β3β4 Loop 8.66 122 59.3 8.7 121.6 59.3 
GLY 315 β3 Sheet 8.677 117.5 44 8.56 117.63 45.9 





Table A.3 continued 
GLN 317 β3 Sheet 9.41 119.11 56.3 9.45 119.44 56.2 
LEU 319 β3 Sheet 8.9 131.5 54.7 9.02 131.4 55 
LEU 320 β3 Sheet 8.87 132.3 52.4 8.59 132.24 52.9 
ALA 333 β3L loop 8.41 124.75 53.17 8.4 124.68 53.1 
MET 336 β3L loop 8.68 116.78 58.5 8.71 116.5 58.5 
HIS 337 β3L loop 8.05 123.77 56.2 8.05 124.2 56.1 
VAL 338 β3L loop 8.04 126.5 61.5 8.04 126.95 62.3 
ASP 339 β3L loop 10.09 131.56 52.5 10.08 131.66 52.3 
PHE 340 β3L loop 9.4 124.85 52.5 9.33 125.1 52.7 
SER 341 β3L loop 8.73 116.23 58.4 8.73 116.3 58.4 
ARG 342 β3L loop 7.17 124.45 57.2 7.19 124.4 57.64 
VAL 369 L Helix 7.15 109.9 60.5 7.3 113.1 61.5 
LYS 372 L Helix 8.8 120.6   8.8 121 59 
ASP 380 Lβ5 Loop 8.1 116.83 54 8.11 116.83 54 
PHE 381 Lβ5 Loop 6.59 119.23 55.98 6.59 119.23 55.98 
SER 382 β5 Sheet 9.02 111.67 57.5 9.01 111.85 57.56 
ILE 383 β5 Sheet 8.41 122.8 61.38 8.49 123 61.45 
ALA 384 β5 Sheet 8.16 131.99 51.97 8.09 131.96 51.7 
GLY 386 β5 Sheet       7.32 109.762 44.5 
ALA 387 β5 Sheet 7.62 124.2 52.8 7.63 123.866 53.3 
GLN 388 β5 Sheet 8.42 123.13   8.38 122.89 55 
ILE 389 β5 Sheet 8.58 127.3 58.9 8.57 127.08 59.7 
GLN 390 β5 Sheet 9.5 130 54.6 9.48 129.78 55.1 
HIS 391 β5 Sheet 9.01 125.7 53.3 8.82 125.43 54.1 
LYS 392 β5 Sheet 8.97 120 56.2 8.86 119.56 55.3 
SER 393 β5 Sheet 8.85 117.9 55.7 8.65 117.65 56 
GLY 394 β5 Sheet 7.07 109.9 46.18 7.02 109.21  
VAL 396 β5 Sheet 6.13 115.2 62.2   62.47 
GLY 398 β5 Sheet 8.68 103.5 44.5 8.59 103.09 46.4 
VAL 399 β5 Sheet 8.03 119.6 62.6   63.3 
GLN 400 β5 Sheet 8.9 126.5 53.3 9.0225 126.47 53.5 
ALA 401 β5 Sheet 7.37 118.53 54.1 7.41 118.14 54 
LEU 402 β5 Sheet 8.65 119.8 56.6 8.74 120.511 55.87 
VAL 405 β5 Sheet 9.22 114.6 59.8 9.2 114.67 60.2 
ALA 409 C term Loop 8.56 121.1 54 8.65 121.93 55 
THR 410 C term Loop 8.09 108.32 62.4 8.01 108.32 62.5 
LYS 412 C term Loop 8.8 121.3 55.3 8.92 121.22 55.87 
ALA 413 C term Loop 7.97 125.8 51.7 8 125.6 52.1 
VAL 414 C term Loop 7.88 127 64 7.83 126.86 64.6 




Table A.4 Example plots of determination of HDX exchange rates in various 
CYP101 forms using peak Intensities (top) and peak volumes (bottom) as a 
























































































GLY 61 -Ligand Free




















































































































GLY 61- Nicotine 































































































Table A.4 table of amide exchange rates for camphor and norcamphor 
A (--) indicates no rates were measured for that residue. A (***) indicates rates could not be measured 












LEU 11 N term Loop Fast  0.0011 0.000401 
ALA 12 N term Loop 0.0009 0.000323 Fast  
HIS 17 N term Loop Fast  Fast  
VAL 18 N term Loop .0431 0.006694 0.0566 0.001175 
LEU 22 N term Loop 0.0045 0.001365 --  
VAL 23 N term Loop 0.00003 0.000242 0.0024 0.0000916 
PHE 24 N term Loop 0.0004 0.0000475 0.0013 0.000395 
PHE 26 N term Loop Fast  0.072 0.008915 
ASP 27 N term Loop 0.085 0.000426 Fast  
TYR 29 N term Loop 0.0003 0.002252 0.0012 0.0003 
ASN 30 N term Loop .0021 0.00086 0.0026 0.00066 
ALA 36 N term Loop Fast  Fast  
GLY 37 A Helix 0.0001 0.000079 Fast  
ASN 49 Aβ1 Loop Fast  0.0005 0.00026 
VAL 50 Aβ1 Loop 0.0105 0.002722 Fast  
VAL 54 β1 Sheet 0.0001 0.000086 0.0011 0.000109 
TRP 55 β1 Sheet 0.00007 0.000062 0.0009 0.000146 
THR 56 β1 Sheet 0.0004 0.00022 0.0011 0.00033 
CYS 58 β1 Sheet 0.0013 0.000309 Fast  
ASN 59 β1 Sheet 0.0438 0.006694 Fast  
GLY 60 β1 Sheet Fast  Fast  
GLY 61 β1 Sheet 0.0007 0.000322 0.0015 0.000315 
HIS 62 β1 Sheet 0.0002 0.000176 0.0008 0.000336 
ILE 64 β1 Sheet 0.00006 0.000055 0.0011 0.000192 
ALA 65 β1 Sheet 0.0001 0.000087 0.0012 0.000141 
THR 66 β1 Sheet 0.00007 0.000054 0.0009 0.00038 
ARG 67 B Helix 0.00007 0.000064 0.0009 0.000214 
GLY 68 B Helix Fast  Fast  
GLN 69 B Helix 0.001 0.000383 Fast  
LEU 70 B Helix Fast  Fast  
CYS 85 BB' Loop 0.0086 0.003085 0.0317 0.006901 
PHE 87 BB' Loop 0.001 0.000598 Fast  
ILE 88 BB' Loop Fast  --  
ARG 90 B' Helix .0055 0.004686 0.00005 0.000212 
GLU 91 B' Helix Fast  Fast  
ALA 92 B' Helix Fast  0.0448 0.004001 
GLY 93 B' Helix Fast  0.0724 0.000003 
GLU 94 B' Helix 0.0002 0.00017 0.00005 0.000226 
ALA 95 B' Helix Fast  0.0188 0.000163 
TYR 96 B' Helix 0.1156 0.00078 Fast  
PHE 98 B'C Loop Fast  --  
VAL 123 C Helix 0.0002 0.000164 0.001 0.000071 
VAL 124 C Helix Fast  0.0011 0.000591 
ASP 125 C Helix Fast  0.0005 0.000105 
LYS 126 C Helix 0.0001 0.000087 0.0016 0.000282 
SER 141 D Helix 0.054 0.010337 Fast  
GLN 145 D Helix .016 0.010276 0.0099 0.001609 
GLY 146 DE Loop .069 0.003446 0.0176 0.001115 
CYS 148 DE Loop 0.0008 0.00021 0.0007 0.000015 





Table A.4 Continued 
PHE 150 E Helix 0.082 0.003755 0.0018 0.000135 
THR 151 E Helix Fast  0.0224 0.00040721 
GLU 152 E Helix Fast  --  
ASP 153 E Helix 0.0001 0.0000804 0.0003 0.0000342 
LEU 165 E Helix 0.0007 0.00038 --  
LEU 166 E Helix 0.0002 0.000159 --  
ALA 167 E Helix 0.0001 0.0000848 0.0007 0.000355 
GLY 168 E Helix 0.055 0.003549 Fast  
GLU 171 EF Loop Fast  Fast  
GLU 172 EF Loop Fast  Fast  
LYS 178 F Helix 0.0006 0.000283 0.0121 0.000163 
TYR 179 F Helix 0.0114 0.000848 0.042 0.000158 
THR 185 F Helix 0.0002 0.000158 Fast  
ASP 188 FG Loop Fast  Fast  
GLY 189 FG Loop 0.1532 0.000768 Fast  
SER 190 FG Loop Fast  0.0082 0.001163 
MET 191 FG Loop Fast  0.0014 0.000076 
THR 192 G Helix 0.0016 0.000415 0.0018 0.000166 
PHE 193 G Helix Fast  Fast  
ALA 194 G Helix 0.153 0.001269 0.0001 0.0000338 
LYS 197 G Helix 0.0007 0.000393 --  
GLU 198 G Helix 0.0021 0.001039 Fast  
ALA 199 G Helix 0.0008 0.000297 Fast  
LEU 200 G Helix 0.0001 0.000088 0.0012 0.000598 
ILE 207 G Helix Fast  0.0401 0.007972 
ILE 208 G Helix 0.0005 0.000253 0.0003 0.0000637 
LYS 214 G Helix 0.0004 0.000256 0.0006 0.000346 
GLY 216 GH Loop Fast  Fast  
ALA 219 H Helix 0.0001 0.000089 --  
ILE 220 H Helix 0.0002 0.000147 Fast  
VAL 223 H Helix 0.0006 0.000292 0.0005 0.0000136 
ALA 224 H Helix 0.0003 0.000177 0.0024 0.0000461 
ASN 225 H Helix 0.0065 0.00078 0.0115 0.000427 
GLY 226 β2 Sheet 0.0557 0.004589 0.0643 0.000322 
GLN 227 β2 Sheet 0.0002 0.00017 0.00007 0.000355 
VAL 228 β2 Sheet 0.2052 0.100309 0.0012 0.000589 
ASN 229 β2 Sheet Fast  --  
GLY 230 β2 Sheet Fast  Fast  
ARG 231 β2 Sheet 0.00002 0.000183 0.0011 0.000498 
ILE 233 β2 Sheet 0.0016 0.000596 0.0057 0.000514 
THR 234 I Helix 0.0215 0.002647 Fast  
ALA 265 I Helix 0.0005 0.000254 0.0007 0.000326 
LYS 266 I Helix Fast  0.0013 0.000521 
SER 267 I Helix .0375 0.00215 0.001 0.000608 
ARG 271 J Helix 0.0015 0.000235 0.0009 0.000245 
GLN 272 J Helix 0.0506 0.00261 0.0121 0.003301 
GLU 273 J Helix Fast  0.0012 0.00008 
LEU 274 J Helix .0017 0.000006 0.0012 0.000266 
GLU 279 JK Loop Fast  Fast  
ARG 280 K Helix 0.0101 0.001928 0.083 0.000269 
ASP 304 β3β4 Loop .0098 0.001587 0.0006 0.00027 
TYR 305 β4 Sheet 0.0003 0.000198 0.0013 0.0000669 
GLU 306 β4 Sheet Fast  Fast  
PHE 307 β4 Sheet 0.0011 0.000402 0.001 0.000301 





Table A.4 Continued 
GLY 309 β4 Sheet Fast  Fast  
VAL 310 β4 Sheet 0.0016 0.000141 0.0013 0.000239 
GLN 311 β4 Sheet 0.0006 0.000332 0.0015 0.000442 
LEU 312 β4 Sheet 0.00006 0.000056 0.001 0.000394 
LYS 313 β3β4 Loop 0.00001 0.000087 0.0016 0.000266 
LYS 314 β3β4 Loop 0.0004 0.000278 0.0008 0.000417 
GLY 315 β3 Sheet Fast  0.0555 0.000278 
ASP 316 β3 Sheet 0.0002 0.000158 0.0018 0.000034 
GLN 317 β3 Sheet 0.1553 0.071454 0.0295 0.0000383 
LEU 319 β3 Sheet 0.00009 0.0000804 0.0019 0.001062 
LEU 320 β3 Sheet 0.0003 0.000161 0.0015 0.000172 
ALA 333 β3L loop Fast  0.0018 0.00015 
MET 336 β3L loop Fast  Fast  
HIS 337 β3L loop 0.0004 0.000225 Fast  
VAL 338 β3L loop Fast  Fast  
ASP 339 β3L loop .0021 0.000568 0.0083 0.001849 
PHE 340 β3L loop Fast  Fast  
SER 341 β3L loop Fast  0.0015 0.000528 
ARG 342 β3L loop Fast  0.1057 0.000539 
VAL 369 L Helix Fast  Fast  
LYS 372 L Helix 0.0008 0.000437 Fast  
ASP 380 Lβ5 Loop 0.0162 0.005133 0.0402 0.000459 
PHE 381 Lβ5 Loop 0.0385 0.003347 0.0075 0.003713 
SER 382 β5 Sheet 0.0002 0.000157 0.0003 0.000027 
ILE 383 β5 Sheet 0.0017 0.0002 0.0049 0.000692 
ALA 384 β5 Sheet 0.037 0.003004 0.0177 0.000303 
GLY 386 β5 Sheet Fast  Fast  
ALA 387 β5 Sheet Fast  Fast  
GLN 388 β5 Sheet 0.0403 0.007308 Fast  
ILE 389 β5 Sheet Fast  Fast  
GLN 390 β5 Sheet Fast  Fast  
HIS 391 β5 Sheet Fast  Fast  
LYS 392 β5 Sheet Fast  0.0013 0.000289 
SER 393 β5 Sheet 0.0002 0.000161 0.0882 0.000851 
GLY 394 β5 Sheet 0.0006 0.000426 0.0143 0.008857 
VAL 396 β5 Sheet 0.0598 0.0000445 --  
GLY 398 β5 Sheet 0.0002 0.000168 0.0045 0.000944 
VAL 399 β5 Sheet 0.0015 0.00051 --  
GLN 400 β5 Sheet 0.00009 0.00008 0.0003 0.000064 
ALA 401 β5 Sheet 0.0293 0.004793 Fast  
LEU 402 β5 Sheet 0.0006 0.000307 0.0013 0.000384 
VAL 405 β5 Sheet 0.00003 .000002 0.00009 0.000358 
ALA 409 C term Loop 0.0004 0.000247 0.0003 0.000118 
THR 410 C term Loop Fast  0.0798 0.0004 
LYS 412 C term Loop Fast  0.0011 0.00044 
ALA 413 C term Loop Fast  Fast  
VAL 414 C term Loop Fast  Fast  
 Total  152  140  
 Fast  52  51  
 Intermediate  40  31  




Table A.5 table of amide exchange rates for Nicotine, Ligand free and 
Ketoconazole 
A (--) indicates no rates were measured for that residue. A (***) indicates rates could not be measured 




















LEU 11 N term Loop 0.0004 0.000005 .0008 0.00059 0.0509 0.005379 
ALA 12 N term Loop Fast  Fast  Fast  
HIS 17 N term Loop Fast  Fast  Fast  
VAL 18 N term Loop .0455 0.002005 0.0644 0.001304 0.0494 0.001518 
LEU 22 N term Loop Fast  0.0064 0.000541 Fast  
VAL 23 N term Loop 0.0005 0.000041 0.0024 0.000033 0.0013 0.000180 
PHE 24 N term Loop .00007 0.000053 0.0024 0.00012 0.0011 0.000087 
PHE 26 N term Loop 0.0003 0.000118 Fast  Fast  
ASP 27 N term Loop Fast  Fast  Fast  
TYR 29 N term Loop 0.0001 0.000039 Fast  0.0001 0.000067 
ASN 30 N term Loop .0504 0.000234 0.0099 0.000455 0.0194 0.000155 
ALA 36 N term Loop Fast  Fast  0.0175 0.004320 
GLY 37 A Helix Fast  Fast  0.0915 0.001086 
ASN 49 Aβ1 Loop .000006 0.000005 0.0007 0.000226 0.0003 0.000091 
VAL 50 Aβ1 Loop 0.0002 0.000176 0.46 0.002722 0.0311 0.002515 
VAL 54 β1 Sheet 0.00005 0.000008 0.0024 0.00011 0.0009 0.000032 
TRP 55 β1 Sheet 0.00003 0.000023 0.0495 0.002632 0.001 0.000121 
THR 56 β1 Sheet 0.00004 0.000005 0.019 0.002578 0.0044 0.001085 
CYS 58 β1 Sheet Fast  0.0013 0.000274 0.0283 0.001085 
ASN 59 β1 Sheet Fast  Fast  Fast  
GLY 60 β1 Sheet Fast  Fast  Fast  
GLY 61 β1 Sheet 0.00004 0.000005 0.0087 0.000327 0.0107 0.000200 
HIS 62 β1 Sheet 0.00005 0.000034 0.0152 0.001798 0.0013 0.000200 
ILE 64 β1 Sheet ***  0.0032 0.000168 0.0008 0.000163 
ALA 65 β1 Sheet 0.000008 0.000007 0.0042 0.00018 0.0016 0.000587 
THR 66 β1 Sheet 0.00001 0.000009 0.0025 0.000156 0.0009 0.000108 
ARG 67 B Helix 0.00001 0.000034 0.0049 0.000038 0.0017 0.000108 
GLY 68 B Helix Fast  Fast  Fast  
GLN 69 B Helix 0.0014 0.000139 0.0012 0.000621 0.04888 0.000299 
LEU 70 B Helix Fast  Fast  Fast  
CYS 85 BB' Loop 0.00005 0.000044 0.0004 0.000288 Fast  
PHE 87 BB' Loop 0.00001 0.000007 --  --  
ILE 88 BB' Loop 0.0002 0.000153 --  --  
ARG 90 B' Helix Fast  Fast  Fast  
GLU 91 B' Helix Fast  Fast  --  
ALA 92 B' Helix 0.0442 0.002878 --  --  
GLY 93 B' Helix Fast  Fast  Fast  
GLU 94 B' Helix 0.00001 0.000009 0.0004 0.000073 0.00005 0.000029 
ALA 95 B' Helix Fast  0.0055 0.002215 Fast  
TYR 96 B' Helix Fast  Fast  Fast  
PHE 98 B'C Loop 0.000005 0.000003 --  --  
VAL 123 C Helix 0.0006 0.000392 0.0173 0.000172 Fast  
VAL 124 C Helix 0.0007 0.000459 Fast  0.0224 0.000553 
ASP 125 C Helix 0.0002 0.000007 --  0.0019 0.000387 
LYS 126 C Helix Fast  0.0036 0.000885 0.0052 0.000736 
SER 141 D Helix 0.0015 0.000011 Fast  Fast  
GLN 145 D Helix Fast  0.088 0.000441 0.0004 0.000218 
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GLY 146 DE Loop 0.0504 0.006732 0.0145 0.00005 0.0217 0.000004 
GLN 147 DE Loop 0.0012 0.000043 0.0012 0.000009 0.0011 0.000027 
CYS 148 DE Loop 0.0011 0.000159 0.0006 0.000024 0.0005 0.000025 
ASN 149 E Helix Fast  0.0196 0.013719 0.0076 0.000004 
PHE 150 E Helix 0.0045 0.000466 0.0025 0.00006 0.0557 0.001953 
THR 151 E Helix Fast  0.0015 0.000103 0.0085 0.000126 
GLU 152 E Helix 0.041 0.001837 0.0014 0.000814 --  
ASP 153 E Helix ***  0.0007 0.000026 0.0004 0.000215 
LEU 165 E Helix --  0.004 0.000263 0.0005 0.000123 
LEU 166 E Helix Fast  --  Fast  
ALA 167 E Helix 0.00007 0.000054 0.0013 0.000031 0.0112 0.002296 
GLY 168 E Helix 0.0538 0.000003 0.0068 0.000003 0.04275 0.000009 
GLU 171 EF Loop Fast  Fast  0.1093 0.001226 
GLU 172 EF Loop Fast  Fast  0.0009 0.000553 
LYS 178 F Helix Fast  0.004 0.000394 0.0672 0.000003 
TYR 179 F Helix 0.008 0.000486 --  --  
THR 185 F Helix 0.0008 0.000368 0.026 0.003589 Fast  
ASP 188 FG Loop 0.0057 0.005700 0.0131 0.000063 0.0005 0.000181 
GLY 189 FG Loop Fast  0.0494 0.000188 Fast  
SER 190 FG Loop 0.0009 0.000577 0.0007 0.000443 0.038 0.001360 
MET 191 FG Loop 0.0018 0.000371 Fast  0.0001 0.000066 
THR 192 G Helix 0.0018 0.000040 Fast  0.041 0.002786 
PHE 193 G Helix Fast  --  --  
ALA 194 G Helix 0.00003 0.000023 0.014 0.001610 Fast  
LYS 197 G Helix 0.0001 0.000041 --  Fast  
GLU 198 G Helix 0.00006 0.000048 0.0233 0.000172 0.0012 0.000088 
ALA 199 G Helix 0.0017 0.000586 Fast  Fast  
LEU 200 G Helix 0.0002 0.000174 0.0158 0.002579 0.0025 0.000685 
ILE 207 G Helix 0.0013 0.000559 0.0007 0.000669 0.0049 0.000958 
ILE 208 G Helix 0.00006 0.000051 0.0011 0.00006 0.0004 0.000230 
LYS 214 G Helix 0.00003 0.000025 Fast  0.0054 0.001433 
GLY 216 GH Loop Fast  Fast  Fast  
ALA 219 H Helix 0.0001 0.000074 --  --  
ILE 220 H Helix 0.0002 0.000066 Fast  Fast  
VAL 223 H Helix 0.00003 0.000026 0.0109 0.000942 0.0027 0.000089 
ALA 224 H Helix 0.00005 0.000039 0.0671 0.000003 0.0162 0.000740 
ASN 225 H Helix --  --  --  
GLY 226 β2 Sheet 0.0982 0.000005 0.0025 0.000122 Fast  
GLN 227 β2 Sheet 0.00007 0.000043 0.0184 0.00043 0.0002 0.000103 
VAL 228 β2 Sheet 0.0327 0.000002 Fast  Fast  
ASN 229 β2 Sheet 0.00003 0.000030 --  --  
GLY 230 β2 Sheet Fast  0.0038 0.000425 Fast  
ARG 231 β2 Sheet 0.00007 0.000059 0.0016 0.00042 0.0003 0.000037 
ILE 233 β2 Sheet 0.0013 0.000139 0.0889 0.000045 Fast  
THR 234 I Helix 0.0002 0.000087 0.0146 0.000836 Fast  
ALA 265 I Helix Fast  0.0004 0.000006 0.014 0.000353 
LYS 266 I Helix 0.00002 0.000014 0.0025 0.000122 0.0003 0.000196 
SER 267 I Helix 0.0012 0.000216 0.0017 0.001212 0.0011 0.000061 
ARG 271 J Helix Fast  0.0016 0.000198 0.0017 0.000111 
GLN 272 J Helix 0.047 0.000366 0.0008 0.000062 0.0003 0.000199 
GLU 273 J Helix 0.0002 0.000046 Fast  Fast  
LEU 274 J Helix 0.0013 0.000072 0.0639 0.004083 0.0005 0.000154 
GLU 279 JK Loop Fast  Fast  Fast  
ARG 280 K Helix 0.1245 0.000730 0.002 0.000146 0.001 0.000397 
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TYR 305 β4 Sheet 0.0001 0.000027 0.0023 0.000131 0.0008 0.000209 
GLU 306 β4 Sheet Fast  Fast  Fast  
PHE 307 β4 Sheet 0.0013 0.000068 0.0032 0.000040 0.0021 0.000042 
HIS 308 β4 Sheet Fast  Fast  Fast  
GLY 309 β4 Sheet Fast  Fast  Fast  
VAL 310 β4 Sheet 0.0021 0.000047 0.0038 0.000045 0.0027 0.000024 
GLN 311 β4 Sheet 0.0263 0.002607 0.0125 0.003048 Fast  
LEU 312 β4 Sheet ***  0.0022 0.000104 0.0014 0.000104 
LYS 313 β3β4 Loop 0.00003 0.000018 0.0594 0.003687 0.0013 0.000046 
LYS 314 β3β4 Loop 0.00005 0.000040 0.00119 0.000040 0.0003 0.000105 
GLY 315 β3 Sheet Fast  0.0197 0.003799 Fast  
ASP 316 β3 Sheet ***  0.019 0.000095 0.0017 0.000536 
GLN 317 β3 Sheet 0.0251 0.000013 Fast  Fast  
LEU 319 β3 Sheet 0.00006 0.000059 Fast  0.0011 0.000705 
LEU 320 β3 Sheet 0.0001 0.000080 0.0044 0.000615 0.0008 0.000105 
ALA 333 β3L loop Fast  0.0003 0.000244 Fast  
MET 336 β3L loop Fast  0.0017 0.00016 0.0064 0.001137 
HIS 337 β3L loop Fast  Fast  Fast  
VAL 338 β3L loop Fast  0.023 0.004431 Fast  
ASP 339 β3L loop 0.0014 0.000241 0.0323 0.001871 0.0754 0.000004 
PHE 340 β3L loop Fast  Fast  Fast  
SER 341 β3L loop Fast  0.0023 0.000187 0.002 0.000074 
ARG 342 β3L loop 0.0503 0.008999 0.089 0.000005 Fast  
VAL 369 L Helix 0.0501 0.002421 Fast  Fast  
LYS 372 L Helix 0.0001 0.000049 0.0017 0.000224 Fast  
ASP 380 Lβ5 Loop 0.0648 0.002731 0.0013 0.000159 0.0003 0.000112 
PHE 381 Lβ5 Loop Fast  0.0064 0.000281 0.0048 0.001009 
SER 382 β5 Sheet 0.000004 0.000004 0.0002 0.000169 0.0008 0.000182 
ILE 383 β5 Sheet 0.0018 0.000431 0.0015 0.000416 0.0005 0.000175 
ALA 384 β5 Sheet 0.0263 0.000001 0.016 0.000175 0.0271 0.000889 
GLY 386 β5 Sheet Fast  Fast  Fast  
ALA 387 β5 Sheet 0.1314 0.000007 0.1035 0.000005 Fast  
GLN 388 β5 Sheet 0.0281 0.000863 Fast  0.0005 0.000161 
ILE 389 β5 Sheet Fast  0.0132 0.002031 Fast  
GLN 390 β5 Sheet Fast  Fast  Fast  
HIS 391 β5 Sheet Fast  Fast  Fast  
LYS 392 β5 Sheet 0.0002 0.000061 0.0195 0.005366 0.0012 0.000136 
SER 393 β5 Sheet 0.00007 0.000040 0.014 0.000246 0.0001 0.000045 
GLY 394 β5 Sheet 0.00002 0.000005 0.026 0.003589 0.0074 0.000177 
VAL 396 β5 Sheet 0.0664 0.000003 --  --  
GLY 398 β5 Sheet 0.00004 0.000015 0.0134 0.001630 0.0408 0.003089 
VAL 399 β5 Sheet Fast  --  --  
GLN 400 β5 Sheet ***  0.0006 0.000034 0.0001 0.000056 
ALA 401 β5 Sheet Fast  --  0.0011 0.000507 
LEU 402 β5 Sheet 0.0002 0.000071 0.0008 0.000123 0.0007 0.000068 
VAL 405 β5 Sheet 0.00001 0.000008 0.0002 0.000033 0.0001 0.000037 
ALA 409 C term Loop Fast  0.0035 0.00004 0.0003 0.000050 
THR 410 C term Loop Fast  Fast  Fast  
LYS 412 C term Loop 0.00004 0.000017 0.0004 0.000291 Fast  
ALA 413 C term Loop 0.000004 0.000004 0.0002 0.000186 0.0306 0.011744 
VAL 414 C term Loop Fast  0.0007 0.000435 0.0567 0.000473 
Total  149  138  139  
Fast  49  40  49  
Intermediate  27  72  50  
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